Category: Nursing

  • Does fentanyl have a high or low first pass effect?

    SCENARIO 2

    Does fentanyl have a high or low 
    first-pass effect
    ? Please discuss why this is important to know and how it relates to 
    bioavailability
    . What route has 100% bioavailability? In addition to parenteral, how can this medication be given to counter the first-pass effect? Write a sample prescription for this medication.
     

    Scenario 2 SOLVED

    The first pass effect of fentanyl is very high. It is extensively metabolised in the liver and the intestines by cytochrome P450 isoenzymes to the metabolite norfentanyl (Rosenthal & Burchum, 2020). This is important to know because it will determine the dose and ultimately the amount of active drug that reaches their cellular site of action. Metabolised drug does not have the same strength as the same quantity that was taken orally. Bioavailability refers to the amount of drug or its active metabolite that reaches the cellular site of action within the body and produces its effects (Rosenthal & Burchum, 2020). Knowing about first-pass effect and its extent for every drug taken orally helps in determining the optimum dose.

    GET ASSIGNMENT HELP HERE

    The route that always assures 100% bioavailability is the parenteral route, as it bypasses the liver. According to Rosenthal and Burchum (2020), transmucosal, transdermal, and sublingual routes are other ways of administering fentanyl that can avoid or reduce the first-pass effect. A sample fentanyl prescription for severe chronic cancer pain is as follows (Medscape, 2025c):

    Fentanyl skin patch (Duragesic) 100 mcg/hr patches, apply 1 (one) patch q72h, #10 RF 1

    Does fentanyl have a high or low first pass effect?

    References

    Medscape (2025c).
    Fentanyl transdermal
    .
    https://reference.medscape.com/drug/duragesic-fentanyl-transdermal-999646

    Rosenthal, L.D., & Burchum, J.R. (2020).
    Lehne’s pharmacotherapeutics for advanced practice providers, 2
    nd
     ed
    . Elsevier.

  • What are the errors in the following prescriptions (5 total)? Rewrite each prescription correctly. What is each medication classification? What is the mechanism of action (MOA)?

    Scenario 1 

    What are the errors in the following prescriptions (5 total)? Rewrite each prescription correctly. What is each medication classification? What is the mechanism of action (MOA)?
     

    Hyzaar (losartan/hydrochlorothiazide) 50/25 mg PO daily #30 3 RF
     

    Lotrel (amlodipine/lisinopril) 5/40 mg PO daily #30 3 RF
     

    hydralizine 25 mg PO QID #120 1 RF
     

    digoxin 1.25 mg PO daily #30 1 RF
     

    Repatha 140 mg IV every 2 weeks #1 1 RF
     

     

    Scenario 1 – SOLVED
    – What are the errors in the following prescriptions (5 total)? Rewrite each prescription correctly. What is each medication classification? What is the mechanism of action (MOA)?

    The clear error in all the five prescriptions in this scenario is that the quantity of the medication strength shown that is to be taken each time (i.e. the number or fraction of tablet to be taken; or the number of vials to be injected) is not indicated (Medical School Headquarters, 2024; OSCEstop Education, 2024). Only the quantity to be dispensed and the refills are shown. For Hyzaar, the dosage strength of HCT given as 25 mg is also wrong. The correct available tablet strength is 50/12.5 mg. Lotrel is the brand name for amlodipine/benazepril. The correct brand name for amlodipine/ lisinopril is Lisonorm, and the correct tablet strength is 5/10 mg. A digoxin dose of 1.25 mg is too high and dangerous. The correct maintenance dose in this case should be 0.125 mg (Rosenthal & Burchum, 2020). The correct prescriptions are thus as follows (Medscape, 2025a; Rosenthal & Burchum, 2020):

    Hyzaar (losartan/hydrochlorothiazide) 50/12.5 mg tablets 1 (one) tablet PO daily, #30, 3 RF

    Lisonorm (amlodipine/lisinopril) 5/10 mg tablets 1 (one) tablet PO daily, #30, 3 RF

    Hydralizine (Apresoline) 25 mg tablets 1 (one) tablet PO QID, #120, 1 RF

    Digoxin (Lanoxin) 0.125 mg tablets 1 (one) tablet PO daily, #30, 1 RF

    Evolocumab (Repatha) 140 mg/mL autoinjector, 1 (one) IV every 2 weeks, #1, 1 RF

    Losartan is an angiotensin II receptor blocker, while HCT is a thiazide diuretic (Rosenthal & Burchum, 2020). Losartan acts by countering the vasoconstriction effects of angiotensin II, thereby causing vessel relaxation and reduction in blood pressure. HCT acts in the renal tubules distally to prevent reabsorption of sodium chloride and hence water. Angiotensin I must be converted into the vasoconstrictor angiotensin II through the catalysis of the enzyme angiotensin converting enzyme or ACE. Lisinopril acts by inhibiting this conversion (Rosenthal & Burchum, 2020). It is therefore an ACE inhibitor by classification.

    BUY A HUMAN-WRITTEN PAPER HERE

    Amlodipine belongs to the class of antihypertensive medications referred to as calcium channel blockers. It acts by interfering with transmembrane Calcium ion transportation into the cells of blood vessels and the heart muscle (Rosenthal & Burchum, 2020). Hydralazine is in a medication class called vasodilators. It is an arteriolar transmembrane calcium channel blocker; an effect that causes arterial vasodilation. Digoxin is a digitalis and a cardiac glycoside by classification. It acts by inhibiting the sodium pump in heart muscle, causing a corresponding increase in intracellular calcium concentrations and force of heart contractions (Rosenthal & Burchum, 2020). Lastly, evolocumab is a monoclonal antibody also known as a PCSK9 inhibitor. It acts by inhibiting the actions of PCSK9 (Medscape, 2025b), thereby lowering the levels of dangerous low-density lipoprotein cholesterol or LDL-C.   What are the errors in the following prescriptions (5 total)? Rewrite each prescription correctly. What is each medication classification? What is the mechanism of action (MOA)?

     

    References

    Medscape (2025a).
    Hydralazine
    .
    https://reference.medscape.com/drug/apresoline-hydralazine-342400#0

    Rosenthal, L.D., & Burchum, J.R. (2020).
    Lehne’s pharmacotherapeutics for advanced practice providers, 2
    nd
     ed
    . Elsevier.

  • streptococcus pyogenes diseases

    Question 30               1 pts

    A 19-year-old has fever, severe sore throat, odynophagia, and tender submandibular nodes. The most likely organism is:

    Group of answer choices

     

    Streptococcus pyogenes

     

    Streptococcus pneumonia

     

    Streptococcus mutans

     

    Streptomyces

  • A patient has a localized nodule on one eyelid which is warm, tender, and erythematous. On examination, the provider notes clear conjunctivae and no discharge. What is the recommended treatment?

    Question 29       1 pts

    A patient has a localized nodule on one eyelid which is warm, tender, and erythematous. On examination, the provider notes clear conjunctivae and no discharge. What is the recommended treatment?

    Group of answer choices

     

    Referral to an ophthalmologist

     

    Surgical incision and drainage

     

    Systemic antibiotics

     

    Warm compresses and massage of the lesion

  • Essay assignment help free

    Essay Assignment Help Free

    The modern academic landscape is defined by a serious demand for excellence, precision, and original thought. For students facing the complexities of higher education, the pressure to produce high-quality papers under tight deadlines can be overwhelming. This has led to a massive surge in searches for “essay assignment help free.” While the digital world is flooded with automated tools and promises of cost-free assistance, discerning students know that quality often requires a professional touch. Among the myriad of options available,
    Online Nursing Papers
    stands out as the premier destination for students seeking specialized, high-authority academic support that is human-written and not AI-generated.

    Essay Assignment Help Free Online

    In 2026, the internet is the first port of call for any student struggling with a complex prompt. The term “essay assignment help free online” encompasses everything from peer-review forums and academic blogs to open-access databases. These resources are invaluable for brainstorming and structuring initial thoughts. However, the limitation of free online help is the lack of personalization. Most free platforms offer generic advice that does not account for specific grading rubrics or institutional requirements.

    This is where 
    Online Nursing Papers
     bridges the gap. While they provide premium, bespoke services, their online resource center offers foundational guidance that helps students understand the nuances of academic writing. By visiting their 
    Services Page
    , students can see the breadth of expertise available, ensuring that their online search for help leads to a verified, professional outcome rather than a dead-end template.

    ORDER HUMAN-WRITTEN PAPER HERE

    Essay Assignment Help Free Download

    Many students seek “essay assignment help free download” options, looking for templates, sample papers, or style guides that they can use as a blueprint. In 2026, downloadable resources have become more sophisticated, often including interactive outlines and citation checklists. These tools are excellent for setting the stage, but they cannot replace the critical thinking required for a top-tier essay.

    Online Nursing Papers
     provides high-quality samples and guides that serve as a gold standard for what an academic paper should look like. Utilizing their 
    Blog and Resource Section
     allows students to download knowledge and insights from experts who understand the current 2026 academic standards. This ensures that even when you are looking for free structural help, the information is grounded in professional reality.

    College Essay Assignment Help Free

    College life is a balancing act of social obligations, part-time work, and intensive study. The search for “college essay assignment help free” is often driven by a need for time management. College-level writing requires a transition from descriptive writing to analytical and argumentative discourse. Many university writing centers offer free tutoring, but these are often overbooked and limited in their scope.

    For students who need more than just a quick proofread, 
    Online Nursing Papers
     offers specialized assistance that caters to the specific rigors of college-level nursing and healthcare curricula. Their experts are familiar with the 2026 standards for evidence-based practice and clinical reasoning, making them a more reliable partner than a generic campus writing center.

    Academic Essay Assignment Help Free

    “Academic essay assignment help free” usually refers to assistance with advanced research papers, case studies, and dissertations. At this level, the stakes are higher, and the need for credible sources is paramount. While open-access journals like 
    PubMed
     provide free data, synthesizing that data into a coherent academic argument is the real challenge.

    Professional services like 
    Online Nursing Papers
     specialize in this synthesis. They offer a level of academic rigor that free tools simply cannot match. By employing writers with advanced degrees, they ensure that every essay is not only grammatically correct but also intellectually robust and compliant with the latest 2026 academic conventions.

    AI Essay Writer Free

    The rise of “AI essay writer free” tools has revolutionized how students approach the first draft. In 2026, AI tools can generate thousands of words in seconds. However, these tools often struggle with “hallucinations”—fabricating facts or citations—and they frequently lack the empathetic “human touch” required in fields like nursing and social sciences.

    While an AI can provide a skeleton, 
    Online Nursing Papers
     provides the soul. Using an AI tool to generate a free draft might save time initially, but it often leads to more work during the editing phase to ensure accuracy. The experts at Online Nursing Papers can take a rough AI-generated concept and refine it into a professional, submission-ready document.

    ChatGPT Essay Writer Free

    As of 2026, “ChatGPT essay writer free” remains one of the most popular searches. ChatGPT is an excellent brainstorming partner and can help students overcome writer’s block. It can suggest titles, outline chapters, and explain complex concepts in simple terms. However, most universities have implemented advanced AI detection software.

    To avoid the pitfalls of academic dishonesty or technical errors associated with AI, students should use ChatGPT as a starting point and then turn to 
    Online Nursing Papers
     for professional polishing. Their human writers ensure that the final product is original, properly cited, and passes all 2026 plagiarism and AI-detection scans.

    Free Essay Generator

    A “free essay generator” is often a “spinbot” or a basic algorithm that rephrases existing content. In the current academic climate, these generators are highly risky. They often produce nonsensical sentences and fail to grasp the context of the assignment. For a student in 2026, relying on a free generator can lead to failing grades or disciplinary action.

    Instead of gambling with an automated generator, students are encouraged to consult the professional writers at 
    Online Nursing Papers
    . Unlike a generator, their writers understand the “why” behind the prompt, ensuring that the essay addresses the core requirements of the rubric with precision and depth.

    Human Essay Writer Free

    While “human essay writer free” sounds like an oxymoron, it typically refers to peer-to-peer help or pro-bono tutoring services. While these can be helpful, they lack the accountability and expertise of a dedicated service. A peer might be able to spot a typo, but they may not understand the intricacies of APA 7th edition or the specific requirements of a 2026 nursing board.

    Online Nursing Papers
     employs human writers who are subject matter experts. They provide a level of mentorship and quality assurance that “free” human help cannot provide. When you 
    Place an Order
    , you are investing in a human connection that ensures your academic success and peace of mind.

    Why Online Nursing Papers is the Best Choice in 2026

    In a world where “free” often means “low quality” or “high risk,” 
    Online Nursing Papers
     offers a premium alternative that guarantees results. Whether you are looking for help with a simple reflection paper or a complex clinical analysis, their team provides:

    Specialized Expertise:
     Deep knowledge of nursing and healthcare fields.

    Originality:
     100% human-written content that passes all 2026 detection tools.

    Timely Delivery:
     Meeting even the most aggressive deadlines.

    Professional Formatting:
     Mastery of APA, MLA, and Chicago styles.

    For students who want to ensure their academic career remains on track in 2026, the choice is clear. Don’t settle for the limitations of “free” when you can have the excellence of 
    Online Nursing Papers
    . Visit their website today to experience the difference that professional academic support can make

  • Minoxidil for hair loss

    Minoxidil for hair loss

    A woman with androgenetic alopecia asks about medication options. You prescribe:

    Group of answer choices

     

    Anthralin

     

    Cyclosporine

     

    Finasteride

     

    Minoxidil

  • NURS-6630 Week 6: Discussion Patient Case Scenario Debate

    NURS-6630 Week 6: Discussion Patient Case Scenario Debate

    In Week 5, you were assigned by Faculty to argue either the pro (for) or con (against) for a particular medication.  You were also provided information for a patient case study scenario. Week 5 was your opportunity to conduct research for this debate.

    This week, you will present and defend your assigned stance (pro or con) and specific medication for your patient case study scenario with your peers. Within the debate, you will also share your perspective on why the alternative medication class would not be appropriate for the patient case scenario.

    Support your answers with evidence-based, peer-reviewed scholarly literature.

    Note:
     APA style format with citations and references will apply.

    As a reminder, these were the assigned medications:

     

    Pro

    Con

    Amphetamine

    Amphetamine

    Methylphenidate

    Methylphenidate

    Alpha Adrenergic Agonist

    Alpha Adrenergic Agonist

    Non-Stimulant

    Non-Stimulant

     

    Resources

     

    Be sure to review the Learning Resources before completing this activity.

    Click the weekly resources link to access the resources.

    WEEKLY RESOURCES

    To prepare:

    Review the Required Learning Resources.

    Review your research regarding your position and medication.

    Consider how you will apply your specific position and medication to the presented patient case.

    By Day 3 of Week 6

    Post 
    your response detailing your argument for the following:

    What is the proposed mechanism of action of the medication(s)? Why might this be appropriate for the patients?

    What are the advantages or disadvantages to your class of medication (options for different administration, length of duration, etc.)?

    What are the advantages or disadvantages to the other medication options?

    What possible side effects or considerations need to be evaluated?

    Provide 
    one
     example for each consideration—legal, ethical, and social implications—for prescribing the medication category.

    Note: Your response needs to be supported by three 3 scholarly peer-reviewed resources located outside of your course learning resources.

    By Day 6 of Week 6

    Read
     a selection of your colleagues’ posts. Focus specifically on those colleagues who were assigned your same medication but opposite stance.

    Respond 
    to 
    at least two
     of your colleagues on 
    2 different days
     who were assigned your same medication but an
     opposite
     stance. For example, if you were assigned the con stance for amphetamine, you should respond to two students who were assigned the pro stance for amphetamine.  Support or expand on your original argument to refute their claims. Work to share additional perspectives on the issue described by your colleague.

    Note:
     It is recommended that you read all peer postings to learn about medications other than those to which you are assigned.
     
    Additionally, your response needs to be supported by 
    two (2)
     scholarly peer-reviewed resources located outside of your course Learning Resources.

     

    SA

    Sherri Arrington

    Apr 2, 2025 11pm
    | Last reply Apr 5, 2025 5:13pm

    Reply from Sherri Arrington

     

    Pro – Methylphenidate for Malcolm, a 9-year-old male in the 4th grade

    What is the proposed mechanism of action of the medication(s)?

    Methylphenidate is a derivative of benzylpiperazine and phenethylamine. Methylphenidate increases dopamine and norepinephrine in the synaptic cleft by blocking the reuptake of norepinephrine and dopamine in the presynaptic neurons. This creates a stimulant effect in the central nervous system, primarily in the prefrontal cortex (Verghese, Patel, & Abdijadid, 2024).

    Why might this be appropriate for the patients?

    Attention Deficit Hyperactivity Disorder (ADHD) is diagnosed in children and adolescents who display symptoms such as increased impulsivity, emotional outbursts, lack of self-control, lack of willingness to follow rules and social norms, lack of concentration in school, being fidgety and unable to sit still during class. This can be attributed to neurodevelopmental disorder where the brain structure is different in the basal ganglia, cerebellum, and prefrontal cortex (Burguete, Peydro, & Ventura, 2025). This is the area of the brain methylphenidate targets.

    What are the advantages or disadvantages to your class of medication (options for different administration, length of duration, etc.)?

    Methylphenidate is available in chewable tablets, oral solution, immediate-release tablets and caplets, extended-release tablets and caplets, oral disintegrating tablets, and transdermal patches. The extended-release is administered one time per day so it can be administered at home and parents do not have to rely on the school system to administer their children a schedule II medication (Verghese, Patel, & Abdijadid, 2024).

    What are the advantages or disadvantages to the other medication options?

    All medications for ADHD have advantages and disadvantages. However, I am supporting methylphenidate as the preferred choice for children diagnosed with ADHD, so I will focus on disadvantages of atomoxetine and amphetamines.

    Atomoxetine has been shown to result in elevated liver enzymes, aggression, suicidal ideation in some patients. Amphetamines have been linked to adverse effects including cardiac events such as coronary artery dissection and hypertensive emergency. Both of these medications are linked to antisocial behavior (Wu, Zhao, Lan, Jin, & Yang, 2025).

    What possible side effects or considerations need to be evaluated?

    The Food and Drug Administration has an Adverse Event Reporting System (FAERS) which is a database that contains reported medication errors and adverse events of medications. FAERS can be accessed by the public sector and health care providers to report real time medication events as they occur. They compared reported adverse events of amphetamines, methylphenidate, and atomoxetine. The major adverse effects of amphetamines involved cardiac and neurologic events, the effects of atomoxetine involved elevated liver enzymes, and the effects of methylphenidate involved precocious puberty (Wu, Zhao, Lan, Jin, & Yang, 2025)

    An important consideration for children with ADHD, especially for parents who strongly oppose medication options, is structured physical exercise (SPE). Sun, Fang, Chan, Poon, Chung, Or, Chen, & Cooper (2024) found that SPE is effective in managing symptoms of ADHD, either alone or as an adjunct to medication. As a grandparent raising a child, age 14, with ADHD, I can share some anecdotal evidence. Our grandchild started playing football in school and we noticed a positive change in his behavior at home and in school. Unfortunately, he sustained a plantaris rupture during off season practice and was unable to practice for 2 months. About one to two weeks out of training, he experienced a shift in his behavior that resulted in phone calls from the school and disciplinary actions at home. My husband mentioned to the school that we strongly suspected his shift in behavior was related to the injury and lack of exercise and/or involvement with his team. He started practicing again today so we will see how it goes, fingers crossed.

    Provide one example for each consideration—legal, ethical, and social implications—for prescribing the medication category.

    Legal considerations are the prescriber will be sure to consider drug interactions, food interactions, and adverse effects of the medication and provide education, verbal with signature to keep on file, and written. This is imperative to ensure the patient and family agree with treatment plan and are aware of the benefits and the risks of the medication. This also ensures they are aware of symptoms to report to the healthcare provider.

    Zaami, Tagliabracci, Berretta, Busardò, & Marinelli, (2020) identified the need for physicians to be cautious in prescribing methylphenidate as a cognitive enhancer, unless there was a real medical need for the medicine. They warned these medications are not designed to help adult patients with procrastination, boredom, or fatigue, and it may not be ethical to prescribe methylphenidate for this purpose. Their suggestions were to patients who seek medications for these reasons is they should use practical methods such as intellectual exercise, education, a rewarding social life, and maintaining a healthy lifestyle rather than resorting to a pill.

    Social considerations for prescribing medications for ADHD could include the lasting impact on the patient as this medication and diagnosisi will always be a part of their medical record and will follow the patient throughout their lifetime. This is especially true today with the electronic health record and easy access to patient’s previous visits to healthcare facilities.

    References

    Burguete, E., Peydro, L., & Ventura, I. (2025). Bioethical evaluation of methylphenidate and

    atomoxetine for pediatric ADHD and cognitive enhancement. 
    Philosophy, Ethics, and Humanities in Medicine 20
    (1). 
    https://doi.rg/10.1186/s13010-025-00167-1 
    Links to an external site.

    Sun, F., Fang, Y., Chan, C. K. M., Poon, E. T. C., Chung, L. M. Y., Or, P. P. L., Chen, Y., &

    Cooper, S. B. (2024). Structured physical exercise interventions and children and

    adolescents with attention deficit hyperactivity disorder: A systematic review and meta‐analysis. 
    Child: Care, Health & Development
    , 
    50
    (1), 1–18. 
    https://doi.org/10.1111/cch.13150
    Links to an external site.

    Verghese, C., Patel, P., & Abdijadid, S. (2024). Methylphenidate. National Library of Medicine.

    Retrieved from 
    Methylphenidate – StatPearls – NCBI BooksheMlf
    Links to an external site.

    Wu L, Zhao D, Lan Y, Jin L, & Yang L. (2025). Comparison of serious adverse effects of

    methylphenidate, atomoxetine and amphetamine in the treatment of ADHD: an adverse event analysis based on the FAERS database. 
    BMC Pharmacology & Toxicology
    , 
    26
    (1),

    Zaami, S., Tagliabracci, A., Berretta, P., Busardò, F. P., & Marinelli, E. (2020). Use of

    Methylphenidate Analogues as Cognitive Enhancers: The Prelude to Cosmetic Neurology and an Ethical Issue. 
    Frontiers in psychiatry
    , 
    10
    , 1006. 
    https://doi.org/10.3389/fpsyt.2019.01006
    Links to an external site.

    Expand discussion thread from Sherri Arrington

    5 Replies, 2 Unread

    5 Replies, 2 Unread

    Reply to post from Sherri Arrington
    Reply

    Mark as Unread
    Mark as Unread

    Clinton C Alozie

    Apr 2, 2025 10:56pm
    | Last reply Apr 5, 2025 4:23pm

    Reply from Clinton C Alozie

    ADHD treatment with Patients’ Scenarios

    Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. For patient 1, Malcolm, psychostimulants Amphetamine and Methylphenidate were selected and are listed as the first-line medications for ADHD symptoms. Studies show that stimulant drugs seem to have a potential protective effect on functional and behavioral outcomes, especially in adolescents with ADHD (Santos et al., 2021). Malcolm, a 9-year-old male who is newly diagnosed with ADHD with active symptoms, will benefit from these medications.

    Mechanism of action
    : The dopamine transporter is known to be blocked by psychostimulants like Methylphenidate. This prevents dopamine from being reabsorbed in the presynaptic terminals and enhances dopamine and norepinephrine releases primarily in the prefrontal cortex (Hamard et al., 2024).

    Results of a meta-analyses study suggest that methylphenidate may improve the ADHD symptoms reported by the teacher, the general behavior reported by the teacher, and the quality of life reported by parents (Santos et al., 2021).

    Advantages of stimulants such as Methylphenidate include high effectiveness in acute symptoms of ADHD
    : Stimulants such as Methylphenidate stand as one of the first-line treatments for ADHD, especially because of their quick-acting nature and effectiveness in improving focus and reducing hyperactivity.

    Disadvantages of stimulants include higher side effects including risk of psychosis
    : Among the potential side effects of these stimulants, a study shows that the risk of onset of psychosis episodes was reported, and when compared between Amphetamine and Methylphenidate, it was concluded that Amphetamine use was associated with a greater risk of psychosis than methylphenidate use (Hamard et al., 2024). Another disadvantage involves high risk for abuse and addiction. The frequently reported side effects are decreased appetite, sleep disturbance, stomachache, and headache, while less frequent is the emergence or worsening of tics (Masi et al., 2022).

    The ethical principle of “do no harm”
    : Prescribers are required by the ethical principle of “do no harm” to weigh the possible advantages of stimulants in reducing symptoms of ADHD against the dangers of dependency and adverse consequences.

    Non-stimulants

    Non-stimulants such as Atomoxetine can also be used to treat Malcolm, however, they can be more appropriate for Patient 2, Jessica.  Atomoxetine, a Selective Norepinephrine Reuptake Inhibitor, works by enhancing the availability of norepinephrine in the brain, thereby improving attention and focus. 
    Some of the advantages include
    : Stimulants may be a better alternative for patients who experience adverse effects of stimulants. Stimulants have a low risk for abuse and addiction when compared to stimulants. At the age of 32, Jessica may be more likely to suffer abuse and addiction to stimulants and will benefit from non-stimulant medication. Like stimulants, they can also improve attention, focus, and impulsiveness NURS-6630 Week 6: Discussion Patient Case Scenario Debate.

    Disadvantages of Non-stimulants
    : Unlike Methylphenidate, one of the major disadvantages of non-stimulants is that for Malcolm’s immediate disturbances in the classroom, non-stimulants might not be the best option because they can take weeks to become fully effective. On the other hand, Jessica, at the age of 32, has less impulsivity and does not physically attack others, a non-stimulant will be more suitable. It might involve a period of trial and error in finding a suitable non-stimulant medication. Hence, Malcolm and his parents may experience weeks or months of frustration as a result of trial and error in determining the appropriate non-stimulant drug and the appropriate dosage. And they are not suitable for all individuals with ADHD. Similarly, both stimulants and non-stimulants can be used effectively in conjunction with cognitive behavioral therapy (CBT) to treat patients with ADHD.

    Side Effects of Non-stimulants
    : Some of the side effects include dry mouth, constipation, drowsiness, and changes in blood pressure and heart rate. These effects are increased with Atomoxetine (Nie, 2023).

    Consideration for legal, ethical, and social implications
    : One consideration when prescribing non-stimulant medication for Jessica includes the ethical principle of informed consent to treatment. To ensure that patients or their guardians can make educated decisions, doctors have an ethical obligation to fully inform patients about the advantages, disadvantages, and alternatives to stimulant medications

    References

     

    Hamard, J., Rousseau, V., Durrieu, G., Garcia, P., Yrondi, A., Sommet, A., Revet, A., &

    Montastruc, F. (2024). Psychosis with use of amphetamine drugs, methylphenidate and atomoxetine in adolescent and adults. 
    BMJ Mental Health
    , 
    27
    (1). 
    https://doi.org/10.1136/bmjment-2023-300876
    Links to an external site.

    Masi, G., Pfanner, C., Liboni, F., Lenzi, F., Villafranca, A., D’Acunto, G., Fantozzi, P., Falcone,

    F., Simonelli, V., Muratori, P., Levantini, V., Favole, I., Amianto, F., Davico, C., & Vitiello, B. (2022). Acute tolerability of methylphenidate in treatment-naïve children with ADHD: An analysis of naturalistically collected data from clinical practice.
     Pediatric Drugs, 24
    (2), 147-154. 
    https://doi.org/10.1007/s40272-022-00492-4
    Links to an external site.

    Nie, T. (2023). Manage early morning ADHD symptoms and functional impairment with

    treatments that are effective from awakening.
     Drugs & Therapy Perspectives, 39
    (8), 287-291. 
    https://doi.org/10.1007/s40267-023-01013-0
    Links to an external site.

    Santos, G. M., Santos, E. M., Mendes, G. D., Fragoso, Y. D., Souza, M. R., & Martimbianco, A.

    C. (2021). A review of Cochrane reviews on pharmacological treatment for attention deficit hyperactivity disorder. 
    Dementia & Neuropsychologia
    , 
    15
    (4), 421–427. 
    https://doi.org/10.1590/1980-57642021dn15-040001
    Links to an external site.

    Expand discussion thread from Clinton C Alozie

    3 Replies, 3 Unread

    3 Replies, 3 Unread

    Reply to post from Clinton C Alozie
    Reply

    Mark as Unread
    Mark as Unread

    AM

    Allan Kasozi Musoke

    Apr 2, 2025 9:09pm
    | Last reply Apr 4, 2025 11:47pm

    Reply from Allan Kasozi Musoke

    Main discussion: Prescription Medications for Amphetamines and Non-Stimulants

    Amphetamines and non-stimulants like Atomoxetine are two standard medication classes used for ADHD treatment, each with distinct mechanisms of action, benefits, and drawbacks. Understanding their appropriateness for different patients is crucial in determining the best treatment approach for Malcolm, a hyperactive and impulsive child, and Jessica, an adult struggling with workplace distractions.

    Amphetamines, such as Adderall (amphetamine-dextroamphetamine), work by enhancing the release of dopamine and norepinephrine in the brain, which improves attention, impulse control, and hyperactivity (Martin & Le, 2023). This mechanism makes amphetamines particularly suitable for Malcolm, who struggles with staying seated, completing tasks, and managing his emotions. The rapid onset of action enables quick symptom relief, allowing him to stay focused in school and follow through with tasks at home. Similarly, amphetamines can benefit Jessica by helping her sustain attention, stay on task at work, and minimize distractions from her coworkers. The availability of different formulations, including short-acting and long-acting options, allows for flexible dosing to accommodate varying daily needs.

    Despite their effectiveness, amphetamines come with notable disadvantages. They have a high potential for abuse and dependency, particularly in adults, making them a less than ideal option for patients with a history of substance use. Common side effects include appetite suppression, insomnia, increased heart rate, and mood changes, all of which require careful monitoring. In children, long-term use may also impact growth. Compared to non-stimulants like Atomoxetine, amphetamines offer faster symptom relief but carry a higher risk of misuse and cardiovascular side effects (Nanda et al., 2023). Legal considerations also play a role, as amphetamines are classified as Schedule II controlled substances, necessitating strict prescribing regulations. Ethically, prescribers must weigh the risk of dependency against the benefits of symptom management, especially in adults. Socially, stimulant medications often carry a stigma, particularly for children, with parents’ concerns about their child being “drugged” for behavioral issues.

    Non-stimulants, such as Atomoxetine (Strattera), offer an alternative treatment option by selectively inhibiting norepinephrine reuptake, thereby improving focus and impulse control without directly affecting dopamine levels (Ilipilla & Arnold, 2024). This makes Atomoxetine an attractive option for Malcolm if his parents prefer a non-stimulant approach or if he has comorbid anxiety, as stimulants can sometimes exacerbate anxiety symptoms. For Jessica, Atomoxetine provides a non-controlled, long-acting solution with 24-hour symptom control, helping her maintain focus throughout the day without the risk of stimulant misuse.

    One of the key advantages of Atomoxetine is that it is not a controlled substance, making it easier to prescribe and manage without strict regulatory restrictions. It also provides consistent symptom control beyond the typical work or school hours, which may benefit adults requiring long-term concentration (Fedder et al., 2023). However, the main drawback of atomoxetine is its delayed onset of action, which takes two to four weeks to notice noticeable improvement. Side effects include nausea, fatigue, and potential increases in blood pressure. While it is less likely to cause addiction or exacerbate anxiety, its efficacy for hyperactivity symptoms may not be as strong as amphetamines. From a legal perspective, Atomoxetine’s status as a non-controlled substance simplifies prescribing but still requires monitoring for potential side effects. Ethically, providers must set realistic expectations for patients, as the delayed onset may lead to frustration. Socially, non-stimulants may be preferred by individuals concerned about addiction or the stigma associated with stimulant use.

                                                                                                                         Conclusion

    Amphetamines and non-stimulants each offer valuable treatment options for ADHD, but the choice of medication should be tailored to the patient’s specific needs and risk factors. For Malcolm, amphetamines provide rapid symptom relief, helping him manage hyperactivity and impulsivity, though concerns about side effects and dependency must be addressed. For Jessica, non-stimulants like Atomoxetine may be a preferable long-term solution, particularly if she wants to avoid stimulant-related risks. Carefully considering efficacy, safety, legal restrictions, and individual preferences is essential in making an informed treatment decision.

     

                                                                                                      References

    Fedder, D., Patel, H., & Saadabadi, A. (2023, March 27). 
    Atomoxetine
    . PubMed; StatPearls Publishing. 
    https://www.ncbi.nlm.nih.gov/books/NBK493234/
    Links to an external site.

    Ilipilla, G., & Arnold, L. E. (2024). The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium. 
    Expert Opinion on Pharmacotherapy
    , 1–12. 
    https://doi.org/10.1080/14656566.2024.2369197
    Links to an external site.

    Martin, D., & Le, J. K. (2023, July 31). 
    Amphetamine
    . PubMed; StatPearls Publishing. 
    https://www.ncbi.nlm.nih.gov/books/NBK556103/
    Links to an external site.

    Nanda, A., Sai, L., Sambe, H. G., Yasir, M., Eyn, R., Gogikar, A., & Mohammed, L. (2023). Adverse effects of stimulant interventions for attention deficit hyperactivity disorder (ADHD): A comprehensive systematic review. 
    Cureus
    , 
    15
    (9). 
    https://doi.org/10.7759/cureus.45995
    Links to an external site.

     

     

    Expand discussion thread from Allan Kasozi Musoke

    6 Replies, 6 Unread

    6 Replies, 6 Unread

    Reply to post from Allan Kasozi Musoke
    Reply

    Mark as Unread
    Mark as Unread

    AM

    Allan Kasozi Musoke

    Apr 2, 2025 9pm

    Reply from Allan Kasozi Musoke

    LT.docx

    Reply to post from Allan Kasozi Musoke
    Reply

    Mark as Unread
    Mark as Unread

    EL

    Elizabeth Longrie

    Apr 2, 2025 8:52pm
    | Last reply Apr 5, 2025 9:03am

    Reply from Elizabeth Longrie

    Main Discussion Post

    (Scenario 1) – 9-year-old

    The first line of treatment for ADHD for both adults and pediatrics are the stimulant medications. For my 9-year-old, I’d prescribe Methylphenidate. This medication’s 
    mechanism of action
     is through the 
    blockage of dopamine and norepinephrine reuptake, leading to the increase of these neurotransmitters’’ in the synaptic cleft (
    Verghese ET AL., 2024)
    . 
    Both Dopamine and norepinephrine promote motivate, focus, alertness and attention.
     
    A decrease in their levels is what leads to ADHD. Therefore, a stimulant would promote their reuptake as discussed.

    Compared to amphetamine which is the other stimulant medication, and commonly prescribed to this population, 
    methylphenidate is often associated with less side effects
    , and have a 
    lower potential of abuse
    . This medication also is available as 
    short-acting, intermediate and long-acting and prides itself in being the most effective as it improves attention, controls hyperactivity and impulsivity (
    Cortese, 2023)
    .

    Some disadvantages/side effects of Methylphenidate include 
    sleep disturbance/concerns, appetite suppression leading to weight loss
     and depending on the formulation used, can 
    only last a few hours
    .

    Legal, ethical and social
     implications of prescribing 
    Methylphenidate
     and 
    Amphetamine
    : Considering these medications are stimulants and have the potential for abuse, stricter prescriptions rules need to be adhered to. A provider needs to monitor refills and ensure it is safely being administered to the intended patient as there’s a risk of this medication to be diverted. A consent is required from the parent or legal guardian when prescribing this medication considering the age of the patient (Pereira ET AL., 2021).

    (Scenario 2) – 32-year-old female

    As opposed to a pediatric, there could be other life stressors contributing to an adult’s ADHD – parenthood, school, job loss et cetera. For my 32-year-old female patient, amphetamines are considered more effective (Chong et al., 2023).

    Mechanism of action:
     being a stimulant, its mechanism of action is similar to that of the methylphenidate in that, it allows for the increment of the amounts of dopamine and norepinephrine in the synaptic cleft, both of which are critical neuro-transmitters in patients with ADHD.

    Advantages: 
    due to its ability to have longer duration of action, it often is more preferred as it only requires a smaller dose to be effective.

    Disadvantages:
     compared to the methylphenidate, amphetamines have the highest potential for dependence and withdrawal symptoms. It also is associated with a greater risk of psychosis.

    Side effects:
     Appetite suppression, GI upset/SLUDGE, Insomnia, palpitations (Martin & Le, 2023).

    Legal, ethical and social
     implications of prescribing Amphetamine: Due to it having a high potential for abuse and misuse, prescribers need to closely monitor refills to help minimize diversion and overdependence. Ethically, it is prudent that providers do not over-diagnose therefore leading to overtreatment.  There’s bound to be peer pressure on patients with prescribed drug of this class due to the meth content therein (Chamakalayil et al., 2021).

    Generally speaking, ADHD has the potential of negatively impacting an individual’s lifestyle if not treated well. It is important that treatment regimen is customized to the individual and all aspects of dynamics taken into account (Sarari et al., 2023).

    References

    Chamakalayil, S., Strasser, J., Vogel, M., Brand, S., Walter, M., & Dürsteler, K. M. (2021). Methylphenidate for Attention-Deficit and Hyperactivity Disorder in Adult Patients With Substance Use Disorders: Good Clinical Practice. 
    Frontiers in psychiatry
    , 
    11
    , 540837. 
    https://doi.org/10.3389/fpsyt.2020.540837
    Links to an external site.

    Chong, T. T., Fortunato, E., & Bellgrove, M. A. (2023). Amphetamines Improve the Motivation to Invest Effort in Attention-Deficit/Hyperactivity Disorder. 
    The Journal of neuroscience : the official journal of the Society for Neuroscience
    , 
    43
    (41), 6898–6908. 
    https://doi.org/10.1523/JNEUROSCI.0982-23.2023
    Links to an external site.

    Cortese, S. (2023). Evidence-based prescribing of medications for ADHD: where are we in 2023? 
    Expert Opinion on Pharmacotherapy
    , 
    24
    (4), 425–434. https://doi.org/10.1080/14656566.2023.2169604

    Martin D, Le JK. Amphetamine. [Updated 2023 Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556103/

    Pereira Ribeiro, J., Arthur, E. J., Gluud, C., Simonsen, E., & Storebø, O. J. (2021). Does Methylphenidate Work in Children and Adolescents with Attention Deficit Hyperactivity Disorder? 
    Pediatric Reports
    , 
    13
    (3), 434-443. 
    https://doi.org/10.3390/pediatric13030050
    Links to an external site.

    Salari, N., Ghasemi, H., Abdoli, N., Rahmani, A., Shiri, M. H., Hashemian, A. H., Akbari, H., & Mohammadi, M. (2023). The global prevalence of ADHD in children and adolescents: a systematic review and meta-analysis. 
    Italian journal of pediatrics
    , 
    49
    (1), 48. https://doi.org/10.1186/s13052-023-01456-1

    Verghese C, Patel P, Abdijadid S. Methylphenidate. [Updated 2024 Oct 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482451/

    Expand discussion thread from Elizabeth Longrie

    3 Replies, 3 Unread

    3 Replies, 3 Unread

    Reply to post from Elizabeth Longrie
    Reply

    Mark as Unread
    Mark as Unread

    Tilahun G Arri

    Apr 2, 2025 8:16pm
    | Last reply Apr 5, 2025 7:54pm

    Reply from Tilahun G Arri

                                        ADHD Medication Classes: Amphetamine vs Non-Stimulant

    This document outlines the pros and cons of two medication classes for ADHD, Amphetamines and Non-simulants, applied to two patient cases: Malcolm, a 9-year-old boy, and Jessica, a 32-year-old woman.

    Mechanism of Action & Appropriateness

    Amphetamine

    – MOA: Increases dopamine and norepinephrine release and inhibits reuptake.

    – Malcolm: FDA-approved for children, effective for hyperactivity and impulsiveness.

    – Jessica: Rapid symptom relief suitable for workplace functioning (Castells et al., 2018.; Cortese et al., 2023).

    Non-Stimulant (e.g., Atomoxetine)

    – MOA: Selective norepinephrine reuptake inhibitor.

    – Malcolm: Suitable if there’s a concern for stimulant misuse or comorbid anxiety.

    – Jessica: Preferred for history of substance use or desire for non-stimulant options (Cojocaru et al., 2021).

    Advantages & Disadvantages

    Amphetamine

    Pros:

    – Rapid onset (30–60 minutes)

    – High efficacy

    – Multiple formulations (short, intermediate, long-acting)

    Cons:

    – Risk of misuse

    – May worsen tics, anxiety, insomnia

    – Requires close monitoring (Cortese et al., 2023).

    Non-Stimulant

    Pros:

    – Lower abuse potential

    – 24-hour coverage

    – Suitable for comorbid anxiety/sleep disorders

    Cons:

    – Slower onset (2–4 weeks)

    – Less effective for some

    – Possible liver enzyme issues or mood changes (Cojocaru et al., 2021).

    Comparative Evaluation

    – Amphetamines offer faster relief but come with a higher risk of side effects and misuse.

    – Non-stimulants are safer for long-term use or patients at risk of misuse but may be slower and less effective. (Cortese et al., 2023).

    Possible Side Effects or Considerations

    Amphetamine

    – Weight loss

    – Insomnia

    – Elevated heart rate/BP

    – Risk of diversion

    (Smith, 2023)

    Non-Stimulant

    – insomnia

    – Fatigue

    – Nausea

    – Mood changes

    (Smith, 2023)

    Legal, Ethical, & Social Implications

    From a legal perspective, amphetamines carry a higher risk of diversion due to their DEA Schedule II status, which mandates strict prescribing guidelines and close monitoring, which is particularly important when prescribing to adolescents, as in Malcolm’s case (Research, 2023). In contrast, non-stimulants are not classified as controlled substances, making them subject to fewer legal restrictions and more accessible for prescribing through telehealth or across state lines.

    On an ethical level, amphetamines present the risk of overprescription or being prescribed without a comprehensive diagnostic evaluation (Dunlop & Newman, 2016). Conversely, choosing non-stimulants to avoid stimulants may delay effective symptom control, which raises ethical concerns, especially when stimulants are clinically indicated.

    The social implications between these medication classes vary significantly. Amphetamines are often stigmatized due to their association with illicit stimulants like ‘speed,’ which can be alarming for parents of young children such as Malcolm. This stigma may lead to concerns about long-term dependency or negative labeling by peers and the broader community (Mueller et al., 2012). On the other hand, non-stimulants may be perceived as less effective or “weaker” treatments. Jessica, for example, might feel that her symptoms are not being taken seriously if she is started on a non-stimulant despite expressing a desire for quick symptom relief.

    Conclusion

    Both amphetamines and non-stimulants can be effective treatments for ADHD, depending on individual patient factors. Malcolm may benefit from a fast-acting stimulant, while Jessica may prefer a non-stimulant for long-term safety and lower risk of misuse.

     

    References

    Castells, X., Blanco-Silvente, L., & Cunill, R. (2018). Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. 
    Cochrane Database of Systematic Reviews
    , 8(8). 
    https://doi.org/10.1002/14651858.cd007813.pub3
    Links to an external site.

    Cortese, S. (2023). Evidence-based prescribing of medications for ADHD: where are we in 2023? 
    Expert Opinion on Pharmacotherapy
    , 24(4). https://doi.org/10.1080/14656566.2023.2169604

    Cojocaru, A., Hogea, L. M., Poroch, V., Simu, M. A., Enatescu, V. R., Jeleriu, R., Andreescu, N. I., Puiu, M., Hogea, B. G., Grigoras, M., Folescu, R., Zamfir, C. L., Enatescu, I., & Nussbaum, L. A. (2021). Effectiveness of Psychostimulant and Non-Psychostimulant Drug Therapy in the Attention Deficit Hyperactivity Disorder. 
    Applied Sciences
    , 11(2), 502. 
    https://doi.org/10.3390/app11020502
    Links to an external site.

    Dunlop, A. J., & Newman, L. K. (2016). ADHD and psychostimulants — overdiagnosis and overprescription. 
    Medical Journal of Australia,
     204(4), 139–139. 
    https://doi.org/10.5694/mja15.01387
    Links to an external site.

    Mueller, A. K., Fuermaier, A. B. M., Koerts, J., & Tucha, L. (2012). Stigma in attention deficit hyperactivity disorder. 
    ADHD Attention Deficit and Hyperactivity Disorders
    , 4(3), 101–114. 
    https://doi.org/10.1007/s12402-012-0085-3
    Links to an external site.

    Research, C. for D. E. and. (2023). Prescription Stimulant Medications. FDA. 
    https://www.fda.gov/drugs/information-drug-class/prescription-stimulant-medications
    Links to an external site.

    Smith, K. T. (2023). ADHD in Children and Adolescents: Barriers to Ethical and Successful Treatment. 
    Journal of Biosciences and Medicines
    , 11(3), 58–63. https://doi.org/10.4236/jbm.2023.113007

     

    Expand discussion thread from Tilahun G Arri

    3 Replies, 3 Unread

    3 Replies, 3 Unread

    Reply to post from Tilahun G Arri
    Reply

    Mark as Unread
    Mark as Unread

    BA

    Beanca Patrice Enojas Abilo

    Apr 2, 2025 7:58pm
    | Last reply Apr 4, 2025 8:53pm

    Reply from Beanca Patrice Enojas Abilo

    Main Post

                
    Amphetamines enhance attention, focus, and impulse control by increasing dopamine and norepinephrine levels in the brain, a mechanism that involves inhibiting the reuptake of these neurotransmitters, thereby improving neurotransmission (Faraone, 2018). Amphetamine, in particular, is indicated as a first line agent for ADHD in adults and for children who are six years old or older (Martin & Le, 2023). One advantage for this medication is its rapid onset. Effects can be experienced within 30 to 45 minutes of taking the medication (Boorady, 2025). In addition, these medications allow flexibility in dosing due to its availability in short-acting and long-acting forms. While amphetamine-based medications are a common and effective treatment for ADHD, research indicates that they are not always well tolerated, and patients may discontinue treatment due to adverse reactions (Castells et al., 2018). The most common adverse effects associated with this class of medications include decreased appetite, insomnia, headaches, abdominal pain, and elevated blood pressure and pulse (Mechler et al., 2022). Amphetamines are also associated with a potential for abuse and are classified as controlled substances. One legal consideration to consider with prescribing amphetamines is the potential for misuse. It is crucial for prescribers to follow the strict guidelines associated with prescribing controlled substances. In terms of ethics, the prescriber must review and balance the benefits of improved health outcomes against the risk of addiction. Furthermore, the potential for social stigma should be considered as this may discourage patients to adhere to their treatment plan. Referring the patient to counseling or providing resources for support groups can help the patient with these challenges.

    Non-stimulant ADHD medications, like atomoxetine (Strattera), can be used as monotherapy or as adjunctive therapy alongside stimulants. This type of medications increases norepinephrine levels in the brain, which help improve attention, focus, and reduce impulsivity and hyperactivity (Fu et al., 2022). An advantage associated with non-stimulant medications is that they have a low abuse potential since they are not controlled substances. In addition, they can provide extended times for symptom control, without peaks and troughs associated with stimulants (Miller & Harper, 2024). On the other hand, non-stimulant medications for ADHD typically take longer to start working compared to stimulants, often requiring several weeks for their full therapeutic effect to be felt (Caldwell, 2025). Common side effects associated with these medications include decreased appetite, nausea, vomiting, fatigue, insomnia (Pang & Sareen, 2021). Non-stimulant medications still require a prescription but are associated with fewer legal concerns due to the lower risk of misuse. Ethical considerations for non-stimulant ADHD medications include ensuring informed consent and reviewing potential side effects and long-term effects with patient. This process allows the patient to practice autonomy and participate in shared decision-making. One social consideration for this class of medications is socioeconomic status. Non-stimulant ADHD medications, like Strattera and Qelbree, can be expensive. However, use of generic options can help reduce cost.

     

    References:

    Boorady, R. (2025, March 5). 
    Stimulant Medications for ADHD
    . Retrieved April 2, 2025, from https://childmind.org/article/understanding-adhd-medications/

    Caldwell, M. (2025, January 12). 
    How Long Does It Take for ADHD Medication to Work?
     Retrieved April 2, 2025, from https://www.thecenterforadhd.com/how-long-does-it-take-for-adhd-medication-to-work/

    Castells, X., Blanco-Silvente, L., & Cunill, R. (2018). Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. 
    The Cochrane database of systematic reviews
    , 
    8
    (8), CD007813. https://doi.org/10.1002/14651858.CD007813.pub3

    Faraone S. V. (2018). The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. 
    Neuroscience and biobehavioral reviews
    , 
    87
    , 255–270. https://doi.org/10.1016/j.neubiorev.2018.02.001

    Fu, D., Wu, D. D., Guo, H. L., Hu, Y. H., Xia, Y., Ji, X., Fang, W. R., Li, Y. M., Xu, J., Chen, F., & Liu, Q. Q. (2022). The Mechanism, Clinical Efficacy, Safety, and Dosage Regimen of Atomoxetine for ADHD Therapy in Children: A Narrative Review. 
    Frontiers in psychiatry
    , 
    12
    , 780921. https://doi.org/10.3389/fpsyt.2021.780921

    Martin, D., & Le, J. K. (2023). Amphetamine. In 
    StatPearls
    . StatPearls Publishing.

    Miller, C., & Harper, T. (2024, December 3). 
    What Are Nonstimulant Medications for ADHD?
     Retrieved April 2, 2025, from https://childmind.org/article/what-are-nonstimulant-medications-for-adhd/

    Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022). Evidence-based pharmacological treatment options for ADHD in children and adolescents. 
    Pharmacology & therapeutics
    , 
    230
    , 107940. https://doi.org/10.1016/j.pharmthera.2021.107940

    Pang, L., & Sareen, R. (2021). Retrospective analysis of adverse events associated with nonstimulant ADHD medications reported to the United States food and drug administration. 
    Psychiatry research
    , 
    300
    , 113861.https://doi.org/10.1016/j.psychres.2021.113861

    Expand discussion thread from Beanca Patrice Enojas Abilo

    3 Replies

    3 Replies

    Reply to post from Beanca Patrice Enojas Abilo
    Reply

    Mark as Unread
    Mark as Unread

    AZ

    Anna Zaretski

    Apr 2, 2025 7pm
    | Last reply Apr 6, 2025 9:31pm

    Reply from Anna Zaretski

    Anna Zaretski

    NURS 6630N-1

    Week 6 Main Post Response 

    Patient #1 
    Malcolm is a 9-year-old fourth-grade student who has recently been diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD), combined presentation. He exhibits hallmark features of both inattention and hyperactivity, including difficulty remaining seated, blurting out responses in class, impulsive physical behaviors such as hitting peers when frustrated, and an inability to sustain attention on tasks at home, such as completing homework or following through with chores. His distractibility also affects daily functioning—for instance, he often leaves tasks incomplete and misplaces important items like the lock combination for the house. These symptoms are interfering with his academic performance, family dynamics, and social relationships, making pharmacologic intervention an important part of his treatment plan.

    Methylphenidate, a central nervous system (CNS) stimulant, is a first-line treatment for pediatric ADHD and would be an appropriate choice for Malcolm. This medication exerts its therapeutic effect by blocking the reuptake of dopamine (DA) and norepinephrine (NE) in the brain, particularly in the prefrontal cortex, where attention, behavioral regulation, and executive functioning are controlled (Stahl et al., 2023). By increasing the availability of these neurotransmitters in the synaptic cleft, Methylphenidate enhances focus, impulse control, and task completion—symptoms that are prominently affecting Malcolm’s daily functioning (Rosenthal & Burchum, 2021). Given Malcolm’s difficulty with sustained attention, impulsivity, and hyperactivity, this medication could significantly improve both his academic and behavioral outcomes.

    One of the key advantages of Methylphenidate is its wide range of formulations, including immediate-release, extended-release, and transdermal patch options. These allow for flexibility in tailoring treatment to meet a child’s daily schedule and minimize the need for in-school dosing, which can reduce stigma and improve adherence (CDC, 2024). The rapid onset of action—typically within 30 to 60 minutes—and duration options ranging from 3 to 12 hours make it a convenient and effective option for school-aged children. Moreover, stimulant medications like Methylphenidate have been shown to reduce core symptoms in up to 70–80% of children with ADHD, improving both behavior and academic functioning (Faraone et al., 2021).

    However, Methylphenidate also carries some disadvantages. It is classified as a Schedule II controlled substance due to its potential for abuse, dependence, and diversion, which necessitates careful monitoring and regulated prescribing (Goodman & Mattingly, 2023). Common side effects include decreased appetite, insomnia, abdominal pain, and mood changes. Long-term use may also impact growth velocity, so regular monitoring of height and weight is essential (Rosenthal & Burchum, 2021). Additionally, cardiovascular health must be evaluated before starting treatment, particularly in children with a family history of cardiac abnormalities.

    While stimulant medications are generally considered the most effective pharmacologic option, non-stimulant alternatives such as atomoxetine or extended-release alpha-agonists (e.g., guanfacine) may be appropriate for children who do not tolerate stimulants well or have coexisting conditions such as anxiety. These alternatives tend to have a slower onset of action and may be less effective at managing hyperactivity and impulsivity (Stahl et al., 2023). Non-pharmacologic interventions, such as behavioral therapy or digital health tools, may also be useful adjuncts but are often less effective when used alone for moderate to severe cases (Pandian et al., 2021; Lindvall et al., 2023).

    Prescribing stimulant medication like Methylphenidate also involves important legal, ethical, and social considerations. Legally, clinicians must adhere to state and federal guidelines for controlled substances, including routine follow-up and documentation for monthly prescriptions. Ethically, informed consent must be obtained from the child’s parents or guardians, ensuring they understand the risks, benefits, and alternatives to treatment—especially given rare but serious risks like sudden cardiac events in predisposed children (Stahl et al., 2023). Socially, stigma surrounding psychiatric medications may impact Malcolm’s self-esteem or peer relationships. Families may also face external judgment or internal concerns about long-term use, emphasizing the need for psychoeducation and collaborative care planning.

    In summary, Methylphenidate offers an evidence-based, flexible, and effective treatment option for Malcolm’s ADHD symptoms. While it requires careful monitoring and informed decision-making, its benefits in improving attention, behavior, and overall functioning can be substantial when combined with supportive care and regular follow-up.

    Patient #2 
    Jessica is a 32-year-old woman recently diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) following a comprehensive psychological assessment. She has experienced longstanding challenges in both academic and occupational settings, frequently receiving disciplinary actions at work for incomplete tasks and difficulty staying focused. Jessica reports becoming easily distracted by conversations with colleagues and often engages in excessive talking, which disrupts others and has led to tension in her professional relationships. Given her symptoms of distractibility, impulsivity, and executive dysfunction, pharmacologic treatment with a central nervous system (CNS) stimulant such as amphetamine may be appropriate to address her impairments in attention and productivity.

    Amphetamine is a mixed salt formulation that includes both dextroamphetamine and levoamphetamine. It is FDA-approved for the treatment of ADHD in adults and is considered a first-line pharmacologic option (CDC, 2024). Amphetamines increase synaptic concentrations of dopamine (DA) and norepinephrine (NE) by promoting their release and inhibiting their reuptake in the central nervous system (Rosenthal & Burchum, 2021). These neurotransmitters are critical for attention regulation, impulse control, and executive functioning—areas where Jessica is currently struggling. By enhancing DA and NE activity in the prefrontal cortex, amphetamines improve focus, task completion, and behavioral regulation, which could help Jessica remain on task and reduce workplace disruptions (Stahl et al., 2023).

    One of the key advantages of amphetamines is their demonstrated efficacy in reducing ADHD symptoms in adults. Approximately 70% of individuals with ADHD report symptom improvement and enhanced quality of life when treated with stimulants (Faraone et al., 2021). Amphetamines are available in both immediate-release and extended-release formulations, allowing for dosing flexibility depending on individual needs. Extended-release forms offer the benefit of once-daily dosing with symptom coverage throughout the workday, improving adherence and reducing the need for mid-day dosing. The onset of action is typically within 30 to 60 minutes, with effects lasting 6 to 12 hours, depending on the formulation.

    Despite their benefits, amphetamines have notable disadvantages. These include the potential for abuse, psychological dependence, and adverse side effects. As Schedule II controlled substances, they are subject to strict prescribing regulations and carry a black-box warning for risk of misuse and serious cardiovascular events, including sudden death in individuals with structural cardiac abnormalities (Goodman & Mattingly, 2023). Common side effects include insomnia, decreased appetite, anxiety, agitation, palpitations, and gastrointestinal disturbances. Patients should be assessed for contraindications such as a history of substance use disorder, cardiovascular disease, hyperthyroidism, and eating disorders. Pregnancy is another consideration, as amphetamines are not recommended due to a lack of controlled studies in pregnant women and potential fetal risks (Stahl et al., 2023).

    In comparison to stimulant medications, non-stimulant options such as atomoxetine or alpha-2 agonists (e.g., guanfacine) may offer benefits for individuals with a history of substance use or those who cannot tolerate stimulants. These alternatives have a lower risk of abuse but may have slower onset of action and reduced efficacy in symptom control (Stahl et al., 2023). Additionally, non-pharmacologic approaches like cognitive-behavioral therapy, physical activity, or digital health tools can be effective adjuncts but may not suffice as standalone treatments for moderate to severe ADHD (Pandian et al., 2021; Lindvall et al., 2023).

    When prescribing amphetamines, it is critical to consider legal, ethical, and social implications. Legally, clinicians must comply with DEA regulations, which include issuing monthly prescriptions and maintaining accurate documentation due to the controlled status of the drug. Ethically, informed consent is essential. Jessica must understand the potential risks and benefits, including the possibility of side effects, misuse, and alternative treatment options. Socially, stigma associated with psychiatric medication can affect patient self-esteem and willingness to adhere to treatment. Jessica may experience judgment or misunderstanding from coworkers or family, so it is important to provide psychoeducation and encourage open communication to foster support and acceptance.

    In summary, amphetamine is a well-supported and effective option for treating ADHD in adults like Jessica. With careful assessment, informed decision-making, and regular follow-up, stimulant therapy can significantly improve her focus, productivity, and quality of life.

                                                                                          References

    Centers for Disease Control and Prevention. (2024, May 15). 
    Treatment of ADHD
    . Centers for Disease Control and

    Prevention.https://www.cdc.gov/adhd/treatment/index.html

    Faraone, S. V., Asherson, P., Banaschewski, T., et al. (2021). Attention-deficit/hyperactivity disorder. 
    Nature Reviews Disease

                 Primers, 7
    (1), 1–21. https://doi.org/10.1016/j.neubiorev.2021.01.022

    Goodman, D. W., & Mattingly, G. (2023). Practice Guidelines Development: The APSARD United States guidelines for the diagnosis

    and treatment of ADHD in adults. 
    Psychiatric Annals,
     
    53
    (10), 449-454–454. 
    https://doi.org/10.3928/00485713-20230911-05
    Links to an external site.

    Lindvall, M. A., Holmqvist, K. L., Philipson, A., Svedell, L. A., Msghina, M., & Cao, Y. (2023). START – physical exercise and

    person-centered cognitive skills training as treatment for adult ADHD. 
    BMC Psychiatry
    , 
    23
    (1). 
    https://doi.org/10.1186/s12888-023-05181-                1
    Links to an external site.

    Pandian, G. S. B., Jain, A., Raza, Q., & Sahu, K. K. (2021). Digital health interventions (DHI) for the treatment of attention deficit

    hyperactivity disorder (ADHD) in children – A comparative review of literature among various treatments and DHI. 
    Psychiatry

                    Research,
     297. 
    https://doi.org/10.1016/j.psychres.2021.113742
    Links to an external site.

    Rosenthal, L. D., & Burchum, J. R. (2021). 
    Lehne’s pharmacotherapeutics for advanced practice nurses and physician

                   
    assistants
    . Elsevier.

    Stahl, S. M., Grady, M. M., & Muntner, N. (2023). 
    Stahl’s essential psychopharmacology: Neuroscientific basis and practical 
     

                  applications
    . Cambridge University Press.

    Expand discussion thread from Anna Zaretski

    4 Replies, 4 Unread

    4 Replies, 4 Unread

    Reply to post from Anna Zaretski
    Reply

    Mark as Unread
    Mark as Unread

    CH

    Crystal Holmes

    Apr 2, 2025 5:52pm
    | Last reply Apr 5, 2025 4:57pm

    Reply from Crystal Holmes

    ADHD is a neurodevelopmental disorder that often persists from childhood into adulthood and can significantly impair academic, occupational, and social functioning.  According to Cortese et al. attention deficit hyperactivity disorder (ADHD) is estimated to affect around 5% of school-age children (aged ≤18 years) and 2.5% of adults worldwide. Some of the signs and symptoms are inattention, hyperactivity, impulsiveness, or combinations. Methylphenidate and Amphetamines are two psychostimulants that treat ADHD. They both work by increasing the availability of dopamine and norepinephrine in the brain but differ in their mechanisms and side effect profiles.

    Mechanism of Action & Clinical Rationale

    Amphetamine is a type of drug that speeds up activity in the brain. It works by raising the levels of certain natural chemicals, mainly dopamine and norepinephrine, and to a lesser extent serotonin which help send messages between brain cells. This boost in brain chemicals can increase alertness, focus, and energy (Martin & Le, 2023). They also inhibit monoamine oxidase at higher doses. This mechanism makes amphetamines effective for both inattentive and hyperactive-impulsive symptoms of ADHD.

    Malcolm:
     Amphetamines may help reduce hyperactivity, impulsiveness, and improve sustained attention in class.

    Jessica:
     As an adult, Jessica may benefit from the longer duration options (e.g., Vyvanse), which can help improve executive functioning, time management, and task completion at work.

     

    Methylphenidate is made from chemicals related to stimulants and works by affecting certain brain messengers. It helps increase the amount of dopamine and norepinephrine two important brain chemicals, by stopping them from being taken back up by nerve cells too quickly. This allows more of these chemicals to stay active between brain cells, which helps improve focus, attention, and alertness (Verghese, Patel, & Abdijadid, 2024). It is slightly less potent than amphetamine at releasing dopamine.

     

    Malcolm:
     Methylphenidate is often first-line in children and has a more established safety profile in pediatrics.

    Jessica:
     It may be a good option if she has concerns about amphetamine-related side effects or potential for misuse.

     

    Advantages and Disadvantages

    Some of the pros & cons of 
    Amphetamine:

    Pros:

    Often longer-acting formulations (e.g., Vyvanse).

    Effective for a wide range of ADHD symptoms.

    Less variability in response between patients.

    Cons:

    Higher potential for side effects like anxiety, insomnia, decreased appetite.

    Higher abuse potential, especially in adults.

    Some may develop tolerance over time.

    Some of the pros & cons of 
    Methylphenidate:

    Pros:

    Available in many formulations (immediate, sustained, extended release).

    Generally, it is better tolerated in children.

    Lower risk of cardiovascular side effects compared to amphetamines.

    Cons:

    May be less effective for some patients.

    Shorter duration in some forms may require multiple doses per day.

    Some patients experience rebound symptoms as medication wears off.

     

    Side Effects

    Amphetamines may cause appetite suppression, frequent insomnia, irritability, and slightly higher cardiovascular and abuse risks compared to Methylphenidate. While Methylphenidate commonly suppresses appetite, it causes less frequent insomnia and lower irritability, cardiovascular risk, and abuse potential than amphetamines.

     

    Legal, Ethical, and Social Considerations

     

    Legal:

    Legal: 
    Both medications are Schedule II controlled substances. It’s imperative to follow DEA regulations and monitor potential misuse or diversion.

    Ethical: 
    Ensuring accurate diagnosis and avoiding over-prescribing is essential, especially in adults who are shopping around for stimulant access is a concern.

    Social:
     Stimulant use can carry stigma. Patients may worry about being labeled as “drug-seeking,” which can affect their willingness to adhere to treatment or disclose their condition.

     

     

    References

    Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., Hollis, C., Simonoff, E., Zuddas, A., Barbui, C., Purgato, M., Steinhausen, H.-C., Shokraneh, F., Xia, J., & Cipriani, A. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. 
    The Lancet Psychiatry, 5
    (9), 727–738. https://doi.org/10.1016/S2215-0366(18)30269-4

    Martin, D., & Le, J. K. (2023, July 31). Amphetamine. In 
    StatPearls
    . StatPearls Publishing. 
    https://www.ncbi.nlm.nih.gov/books/NBK556103/
    Links to an external site.

    Verghese, C., Patel, P., & Abdijadid, S. (2024, October 29). Methylphenidate. In 
    StatPearls
    . StatPearls Publishing. 
    https://www.ncbi.nlm.nih.gov/books/NBK482451/
    Links to an external site.

     

     

     

     

     

     

     

    Expand discussion thread from Crystal Holmes

    2 Replies, 2 Unread

    2 Replies, 2 Unread

    Reply to post from Crystal Holmes
    Reply

    Mark as Unread
    Mark as Unread

    AA

    Adebimpe Adepitan

    Apr 2, 2025 5:25pm
    | Last reply Apr 5, 2025 12:56am

    Reply from Adebimpe Adepitan

    Pro Argument for Methylphenidate in ADHD Management

    The central nervous system stimulant methylphenidate functions by blocking the prefrontal cortex dopamine and norepinephrine reuptake to enhance neurotransmission and improve attention control with executive function (Zetterström et al., 2022). Through this effect, methylphenidate specifically helps patients who have ADHD because it acts directly on the disease-induced neurobiological deficits. Methylphenidate presents reduced risks for dependency alongside cardiac problems compared to amphetamines, which makes it a preferred choice for patients with low cardiovascular vulnerability (Zetterström et al., 2022). Treatments based on individual patient needs and lifestyle requirements can be accomplished through methylphenidate’s availability as immediate-release (IR) and extended-release (ER) formulations.

    The alternative treatments, which include alpha-adrenergic agonists together with non-stimulants (such as atomoxetine), exhibit inferior performance for rapid improvement of core ADHD symptoms. Alpha-adrenergic agonists clonidine and guanfacine demonstrate their best effect on norepinephrine signaling pathways while offering suitable management for patients who experience tic disorders or anxiety (Ilipilla & Arnold, 2024). These medications do not increase dopamine signaling directly, which makes them less beneficial for those needing urgent cognitive improvement. The selective norepinephrine reuptake inhibitor atomoxetine needs multiple weeks for complete therapeutic effectiveness because it delays symptom relief. The immediate benefits of methylphenidate treatment enable its use as the primary selection for treating numerous patients (Aldosary et al., 2021).

    The decision process of prescribing methylphenidate requires healthcare providers to consider legal aspects alongside ethical concerns and social implications. The pharmacological status of this substance makes it a Schedule II controlled drug, which demands stringent prescription tracking systems to prevent its unintended misuse and unauthorized distribution (Aldosary et al., 2021). Health providers should balance patient dependency risk and medical need when prescribing medication while providing informed consent and instructing patients about suitable medication use. Social stigmas regarding stimulant medications lead both patients’ parents and school personnel to sometimes avoid their prescribed use because of these negative social perceptions. Addressing these issues through patient-centered care and public awareness initiatives is crucial for optimizing treatment outcomes while minimizing risks (Mwesigwa & Shibao, 2024).

     

    References

    Aldosary, F., Norris, S., Tremblay, P., James, J. S., Ritchie, J. C., & Blier, P. (2021). Differential potency of Venlafaxine, Paroxetine, and atomoxetine to inhibit serotonin and norepinephrine reuptake in patients with major depressive disorder. 
    International Journal of Neuropsychopharmacology
    , 
    25
    (4), 283-292. 
    https://doi.org/10.1093/ijnp/pyab086
    Links to an external site.

    Ilipilla, G., & Arnold, L. E. (2024). The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium. 
    Expert Opinion on Pharmacotherapy
    , 
    25
    (8), 945-956. 
    https://doi.org/10.1080/14656566.2024.2369197
    Links to an external site.

    Mwesigwa, N., & Shibao, C. A. (2024). Norepinephrine reuptake inhibition, an emergent treatment for neurogenic orthostatic hypotension. 
    Hypertension
    , 
    81
    (7), 1460-1466. 
    https://doi.org/10.1161/hypertensionaha.124.22069
    Links to an external site.

    Zetterström, T. S., Quansah, E., & Grootveld, M. (2022). Effects of methylphenidate on the dopamine transporter and beyond. 
    Current Topics in Behavioral Neurosciences
    , 127-157. 
    https://doi.org/10.1007/7854_2022_333
    Links to an external site.

    Expand discussion thread from Adebimpe Adepitan

    1 Reply, 1 Unread

    1 Reply, 1 Unread

    Reply to post from Adebimpe Adepitan
    Reply

    Mark as Unread
    Mark as Unread

    AH

    Armine Hayrapetyan

    Apr 2, 2025 4:33pm
    | Last reply Apr 5, 2025 8:08pm

    Reply from Armine Hayrapetyan

    Patient 1 (Malcom 9-year old)

    Following Malcom’s diagnosis, ADHD, a non-stimulant medication like Atomoxetine (Strattera) can be considered. It is a medication that is used when stimulant medication fails to be effective or result to intolerable side effects.

    Mechanism of Action

    The non-stimulant medication (Atomoxetine) works through increasing norepinephrine levels, which is a neurotransmitter in the brain that assists in controlling attention, behavior, and emotions (Docherty & Alsufyani, 2021). This may be appropriate for the patient as it can help him have concentrate better, be less hyperactive and be less impulsive.

    Advantages & Disadvantages of the Non-Stimulant (Atomoxetine)

    The advantages include; it can be take twice or once in a day that may be convenient for the family and it is not a controlled substance; hence, it has no potential of physical dependence or abuse.

    The disadvantage is that it may take more weeks to see full effects and it can result to side effects like dizziness, stomach upset, decreased appetite and nausea.

    Advantages and Disadvantages of other Medication Options- Methylphenidate

    Methylphenidate is a stimulant medication that is considered as first-in-line ADHD treatments. The advantage is that it works more effectively and quicker compared to non-stimulants. It improves focus and attention, reduce impulsivity and enhance behavior (Ryst & Childress, 2023). The disadvantage is that they have a higher potential for physical dependence

    and abuse and can result to side effects like mood swings, decreased appetite and sleep problems.

    Side Effects and Considerations

    The non-stimulant, Atomoxetine, can result to side effects like dizziness, stomach upset, decreased appetite and nausea. In addition, it can result to even serious side effects like liver damage; hence, it requires regular monitoring.

    Legal, ethical and social implications Legal: Atomoxetine prescription should be according to the state and local laws and regulation, including minor rights as well as informed consent.

    Ethical: The decision of prescribing medication needs to be made in the best interest of the patient, following the potential risks and benefits.

    Social: There may be stigma linked to taking mental health condition medication that may affect Malcom’s social interactions and self-esteem. It is crucial to address this issue and offer support when needed.

     

    Patient 2, Jessica, 32-year-old female

    Mechanism of Action: Alpha adrenergic agonist

    Alpha adrenergic agonist work thorough stimulation of the brain’s alpha-adrenergic receptors. This stimulation leads to an increase of norepinephrine concentration in the synaptic cleft that in turn improves signals transmission in the brain; hence, enhancing attention as well as reducing hyperactivity and impulsivity (Ilipilla & Arnold, 2024).

    Disadvantages of Alpha Adrenergic Agonist

    Alpha adrenergic agonist such as guanfacine and clonidine have both advantages and disadvantages. They offer advantages like lowering blood pressure, improve focus, and reduce impulsivity and hyperactivity. The disadvantages include; they can lead to side effects like constipation, drowsiness, and dry mouth; they have shorter duration of action; hence, need multiple doses throughout the day, and many not be as effective as stimulant medications in relation to treating ADHD symptoms (Ilipilla & Arnold, 2024).

    Advantages and Disadvantages of other ADHD medications (Amphetamines)

    The advantages of the amphetamines are that they have longer duration of action, needing fewer doses and they are generally more effective in relation to treating ADHD symptoms. The disadvantages are that they can cause side effects like nervousness, fever, insomnia, emotional lability and loss of appetite (Docherty & Alsufyani, 2021).

    Side effects of Alpha Adrenergic Agonist

    The possible side effects constitute, drowsiness, constipation, dry mouth, slower heart rate, and lower blood pressure.

    Legal, Ethical and Social Implications

    Legal: Misuse of Alpha Adrenergic Agonist can result to legal consequences.

    Ethical: it is essential to use the medication only as prescribed.

    Social: Misuse of the medications can result to social stigma. For instance, an individual can get labelled as “drug user”.

    References

    Docherty, J. R., & Alsufyani, H. A. (2021). Pharmacology of drugs used as stimulants. The Journal of Clinical Pharmacology, 61(S2). 
    https://doi.org/10.1002/jcph.1918
    Links to an external site.

    Ilipilla, G., & Arnold, L. E. (2024). The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium. Expert Opinion on Pharmacotherapy, 25(8), 945- 956. 
    https://doi.org/10.1080/14656566.2024.2369197
    Links to an external site.

    Ryst, E., & Childress, A. (2023). An updated safety review of the current drugs for managing ADHD in children. Expert Opinion on Drug Safety, 22(11), 1025-1040. 
    https://doi.org/10.1080/14740338.2023.2271392
    Links to an external site.

    Expand discussion thread from Armine Hayrapetyan

    2 Replies, 2 Unread

    2 Replies, 2 Unread

    Reply to post from Armine Hayrapetyan
    Reply

    Mark as Unread
    Mark as Unread

    IJ

    Ibiene Mary Jumbo

    Apr 2, 2025 4:30pm

    Reply from Ibiene Mary Jumbo

    Mechanism of Action and Appropriateness for the Patient

    Amphetamine is a central nervous system stimulant that increases dopamine and norepinephrine levels by inhibiting reuptake and promoting neurotransmitter release (Faraone, 2018). This mechanism improves attention, focus, and impulse control, making it highly effective for treating ADHD. Given the patient’s symptoms of inattention and hyperactivity, this medication provides immediate symptom relief and enhances executive functioning.

    Advantages:

    Multiple formulations (short-acting and long-acting) allow for flexible dosing.

    Proven efficacy in improving ADHD symptoms and executive function (Fredriksen et al., 2013).

    Rapid onset of action, beneficial for individuals needing immediate symptom control.

    Disadvantages:

    Potential for misuse and dependency, particularly in adolescents and young adults (Weyandt et al., 2016).

    Can cause insomnia, decreased appetite, and cardiovascular concerns in some patients (Weyandt et al., 2016).

    Requires close monitoring due to risk of increased blood pressure and heart rate (Weyandt et al., 2016).

    Advantages and Disadvantages of Alternative Medication Class

    Alternative medications, such as non-stimulants (e.g., atomoxetine) or alpha-adrenergic agonists (e.g., guanfacine), offer non-addictive options for ADHD treatment. However, they also come with limitations (Newcorn et al., 2022).

     
    Advantages of Non-Stimulants and Alpha-Agonists:

    Lower abuse potential compared to stimulants.

    Can be beneficial for patients with comorbid anxiety or tic disorders.

    Disadvantages of Non-Stimulants and Alpha-Agonists:

    Delayed onset of action (weeks to months to achieve full efficacy) (Newcorn et al., 2022).

    Less effective for improving executive function compared to stimulants (Newcorn et al., 2022).

    Common side effects include sedation, dizziness, and hypotension (Newcorn et al., 2022).

    Side Effects and Considerations

    Stimulants: Potential for cardiovascular issues, appetite suppression, and insomnia.

    Non-Stimulants: May cause mood changes, fatigue, and gastrointestinal issues (Newcorn et al., 2022).

    Alpha-Agonists: Can lead to hypotension, sedation, and dizziness.

    Legal, Ethical, and Social Considerations

    Legal: Controlled substance regulations require careful prescribing and monitoring to prevent misuse (Drug Enforcement Administration, 2019).

    Ethical: Balancing the benefits of treatment with the potential risks of stimulant dependency requires informed consent and patient education (Wilens et al., 2021).

    Social: The stigma surrounding stimulant medications may affect adherence and perception of treatment among patients and families.

    Conclusion

    The assigned medication [Amphetamine/Methylphenidate/Alpha-Agonist/Non-Stimulant] provides substantial benefits in treating ADHD, though it requires careful monitoring. Alternative medications have their place in treatment but may be less effective for immediate symptom control. An individualized approach is necessary to optimize outcomes based on the patient’s medical history, risk factors, and treatment goals.

    References

    Drug Enforcement Administration. (2019). 
    Stimulants | DEA
    . Dea.gov. https://www.dea.gov/taxonomy/term/346

    Faraone, S. V. (2018). The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. 
    Neuroscience & Biobehavioral Reviews
    , 
    87
    , 255–270. https://doi.org/10.1016/j.neubiorev.2018.02.001

    Fredriksen, M., Halmøy, A., Faraone, S. V., & Haavik, J. (2013). Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: A review of controlled and naturalistic studies. 
    European Neuropsychopharmacology
    , 
    23
    (6), 508–527. https://doi.org/10.1016/j.euroneuro.2012.07.016

    Newcorn, J. H., Krone, B., & Dittmann, R. W. (2022). Nonstimulant Treatments for ADHD. 
    Child and Adolescent Psychiatric Clinics of North America
    , 
    31
    (3). https://doi.org/10.1016/j.chc.2022.03.005

    Weyandt, L. L., Oster, D. R., Marraccini, M. E., Gudmundsdottir, B. G., Munro, B. A., Rathkey, E. S., & McCallum, A. (2016). Prescription stimulant medication misuse: Where are we and where do we go from here? 
    Experimental and Clinical Psychopharmacology
    , 
    24
    (5), 400–414. https://doi.org/10.1037/pha0000093

     

    Reply to post from Ibiene Mary Jumbo
    Reply

    Mark as Unread
    Mark as Unread

    LF

    Lutaline Fosah

    Apr 2, 2025 2:38pm
    | Last reply Apr 4, 2025 10:32am

    Reply from Lutaline Fosah

    Initial Discussion

    Amphetamine and Methylphenidate in ADHD Treatment

    Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity. Pharmacological treatment plays a crucial role in managing ADHD symptoms, mainly through stimulant medications like amphetamine and methylphenidate. This discussion will evaluate these two medication classes, their mechanisms of action, benefits, drawbacks, and implications in the cases of Malcolm, a 9-year-old child, and Jessica, a 32-year-old adult.

    Mechanism of Action and Appropriateness for Patients

    Amphetamines, including dextroamphetamine and lisdexamfetamine, function by increasing dopamine and norepinephrine levels in the brain. They achieve this by stimulating the release of these neurotransmitters and inhibiting their reuptake, enhancing attention and impulse control (Goldin, 2023). Given Malcolm’s hyperactivity, impulsivity, and inability to focus, amphetamines could be a practical choice in regulating his behavior and improving his executive function. Similarly, Jessica’s workplace difficulties due to distractibility and impulsivity indicate that amphetamines may enhance her ability to complete assigned tasks and maintain professional relationships.

    Methylphenidate also increases dopamine and norepinephrine levels but does so primarily by blocking their reuptake rather than stimulating their release (Stahl, 2021). This mechanism results in improved attention and reduced impulsivity, making it appropriate for both Malcolm and Jessica. While both medications are stimulants, methylphenidate is often preferred in pediatric cases due to its slightly lower risk of increased heart rate and blood pressure (Pitzianti et al., 2020).

    Advantages and Disadvantages of Amphetamine and Methylphenidate

    Amphetamines offer the advantage of various administration options, including immediate-release (IR), extended-release (ER), and prodrug formulations like lisdexamfetamine, which provides a smoother onset and longer duration (Abbas et al., 2024). This flexibility allows for tailored dosing schedules. However, amphetamines have a higher potential for misuse and dependence, which is particularly concerning for adults like Jessica who may be at risk of substance use disorders.

    Methylphenidate, in contrast, has a slightly lower abuse potential and offers similar immediate-release and extended-release formulations. Moreover, it has a more predictable effect duration, which is useful for younger children like Malcolm, ensuring symptom control during school hours without excessive stimulation in the evenings (Pitzianti et al., 2020). Nevertheless, methylphenidate has a shorter half-life compared to some amphetamine formulations, necessitating multiple daily doses in some cases.

    Comparison with Other Medication Options

    Alpha-adrenergic agonists, such as guanfacine and clonidine, provide an alternative non-stimulant treatment. They work by targeting noradrenergic receptors in the prefrontal cortex, reducing hyperactivity and impulsivity (Su et al., 2023). While they are beneficial for patients who cannot tolerate stimulants, they are less effective for attention-related symptoms and may cause sedation.

    Non-stimulant medications like atomoxetine, a selective norepinephrine reuptake inhibitor, offer another alternative. They lack the abuse potential of stimulants and provide 24-hour symptom control, making them suitable for adults with ADHD and comorbid anxiety. However, their delayed onset of action (several weeks) and side effects such as nausea and fatigue limit their immediate efficacy (Stahl, 2021).

    Side Effects and Considerations

    Both amphetamine and methylphenidate can cause insomnia, decreased appetite, increased heart rate, and mood swings. In children like Malcolm, appetite suppression can be particularly concerning for growth and development. In adults like Jessica, cardiovascular side effects should be monitored due to potential hypertension risks. Additionally, both medications may exacerbate anxiety symptoms, requiring careful titration and monitoring (Goldin, 2023).

    Legal, Ethical, and Social Implications

    Legally, stimulant medications are classified as Schedule II controlled substances due to their potential for abuse and dependence. This classification requires strict prescribing guidelines, including limited refill options and regular patient evaluations. Healthcare providers must ensure appropriate documentation and risk assessment before prescribing these medications (Abbas et al., 2024).

    Ethically, prescribing stimulants to children like Malcolm involves considerations of informed consent and parental responsibility. Parents must be educated on medication risks and benefits, and healthcare providers must ensure that pharmacological interventions align with behavioral therapies to maximize outcomes.

    Socially, ADHD medications can carry stigma, particularly for adults like Jessica, who may face workplace bias or misconceptions regarding stimulant use. Additionally, disparities in access to ADHD medication raise concerns, as individuals from lower socioeconomic backgrounds may have limited healthcare access, leading to underdiagnosis and undertreatment.

    Conclusion

    Both amphetamine and methylphenidate offer effective symptom control for ADHD, though each has unique advantages and drawbacks. Amphetamines provide longer-lasting effects but pose a higher risk of abuse, whereas methylphenidate offers more controlled symptom management with a lower side effect burden. While non-stimulant options exist, they may not provide immediate symptom relief. In prescribing these medications, legal, ethical, and social factors must be carefully considered to ensure appropriate and equitable ADHD treatment.

    References

    Abbas, K., Barnhardt, E. W., Nash, P. L., Streng, M., & Coury, D. L. (2024). A review of amphetamine extended release once-daily options for the management of attention-deficit hyperactivity disorder. 
    Expert Review of Neurotherapeutics
    , 24(4), 421–432. 
    https://doi.org/10.1080/14737175.2024.2321921
    Links to an external site.

    Goldin, D. S. (2023). 
    Fast facts for psychopharmacology for nurse practitioners
    . Springer Publishing.

    Pitzianti, M. B., Spiridigliozzi, S., Bartolucci, E., Esposito, S., & Pasini, A. (2020). New insights on the effects of methylphenidate in attention deficit hyperactivity disorder. 
    Frontiers in Psychiatry
    , 11, 531092. 
    https://doi.org/10.3389/fpsyt.2020.531092
    Links to an external site.

    Stahl, S. M. (2021). 
    Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.).
     Cambridge University Press.

    Su, M., Wang, J., Xiang, G., Do, H. N., Levitz, J., Miao, Y., & Huang, X. (2023). Structural basis of agonist specificity of α1A-adrenergic receptor. 
    Nature Communications
    , 14(1), 1-12. 
    https://doi.org/10.1038/s41467-023-40524-2
    Links to an external site.

    Expand discussion thread from Lutaline Fosah

    1 Reply, 1 Unread

    1 Reply, 1 Unread

    Reply to post from Lutaline Fosah
    Reply

    Mark as Unread
    Mark as Unread

    EE

    Emmanuel C Ezeala

    Apr 2, 2025 1:45pm
    | Last reply Apr 6, 2025 11:42am

    Reply from Emmanuel C Ezeala

     

     

     

    Main Post.

    Mechanism of Action of Methylphenidate

    Methylphenidate is a central nervous system (CNS) stimulant that primarily works by inhibiting the brain’s reuptake of dopamine and norepinephrine. By blocking the dopamine transporter (DAT) and the norepinephrine transporter (NET), methylphenidate increases the availability of these neurotransmitters in the synaptic cleft, leading to enhanced neurotransmission (Arnsten & Rubia, 2012). This action helps improve attention, impulse control, and hyperactivity symptoms in individuals with ADHD (Biederman et al., 2019).

     
    Appropriateness of Methylphenidate for Malcolm

    Methylphenidate is appropriate for Malcolm because it addresses the core symptoms of ADHD and combined presentation, including impulsiveness, hyperactivity, and inattentiveness. Clinical trials have demonstrated that methylphenidate effectively reduces ADHD symptoms in children, leading to improved behavioral regulation, academic performance, and social interactions (Storebø et al., 2018). Given Malcolm’s struggles with impulsivity, distractibility, and difficulty completing tasks, this medication is expected to provide meaningful symptom relief.

     
    Advantages and Disadvantages of Methylphenidate

    Advantages:

     
    Administration:
     Available in multiple formulations, including immediate-release (IR), sustained-release (SR), and extended-release (ER), allowing for flexibility in dosing (Cortese et al., 2020).

    Duration:
     ER formulations provide symptom relief throughout the school day with a single morning dose, reducing the need for midday dosing.

    Efficacy:
     Demonstrates significant improvement in ADHD symptoms compared to placebo, with effects noticeable within 30–60 minutes of administration (Biederman et al., 2019).

     
    Disadvantages:

     
    Side Effects:
     Common side effects include appetite suppression, sleep disturbances, irritability, and gastrointestinal discomfort (Storebø et al., 2018).

    Duration Considerations:
     IR formulations require multiple daily doses, possibly leading to compliance issues.

    Potential for Misuse:
     As a Schedule II controlled substance, there is a risk of misuse or diversion (Cortese et al., 2020).

     
    Comparison to Other Medication Options

    Alternative medications for ADHD include amphetamines (e.g., lisdexamfetamine), non-stimulants (e.g., atomoxetine, guanfacine, clonidine), and behavioral interventions.

    Amphetamines
    : Similar efficacy to methylphenidate but may have a higher risk of side effects such as increased heart rate and blood pressure.

    Atomoxetine (Strattera)
    : A non-stimulant selective norepinephrine reuptake inhibitor, suitable for patients with comorbid anxiety or risk of substance misuse but with a delayed onset of action (2–4 weeks).

    Guanfacine/Clonidine
    : Alpha-2 adrenergic agonists are helpful for hyperactivity and impulsive but can cause sedation and hypotension.

     
    Side Effects and Considerations

    Malcolm should be monitored for potential side effects, including reduced appetite, weight loss, sleep disturbances, and mood changes. Parents should be educated on proper administration to minimize rebound effects and ensure adherence. Additionally, periodic growth and cardiovascular function assessment is recommended (Cortese et al., 2020).

     
    Legal, Ethical, and Social Considerations

     
    Legal:
     As a controlled substance, methylphenidate requires careful prescribing and monitoring to prevent misuse and ensure compliance with regulations. Providers must educate parents on proper storage and adherence (Biederman et al., 2019).

    Ethical:
     The decision to medicate a child for ADHD involves balancing benefits with potential risks, ensuring informed consent from caregivers, and considering alternative interventions.

    Social:
     Stimulant medications may carry stigma, leading to concerns about labeling and self-esteem in children diagnosed with ADHD. Schools and caregivers should foster an understanding and supportive environment.

     
    Mechanism of Action of Amphetamine

    Amphetamines function by increasing the levels of dopamine and norepinephrine in the brain. They do this primarily by promoting the release of these neurotransmitters from presynaptic neurons and inhibiting their reuptake, which enhances neurotransmitter availability in the synaptic cleft. This mechanism improves attention, impulse control, and executive functioning, which are often impaired in individuals with ADHD (Volkow et al., 2021).

     
    Appropriateness of Amphetamine for Jessica

    Given Jessica’s difficulties with task completion, distractibility, and excessive talking, amphetamine is an appropriate choice as it enhances focus and reduces impulsiveness. Research shows that stimulant medications like amphetamine significantly improve ADHD symptoms in adults, allowing for better job performance and social interactions (Biederman et al., 2019).

     
    Advantages and Disadvantages of Stimulant Medications

    Advantages:

     
    High Efficacy:
     Stimulants are among the most effective treatments for ADHD, with symptom improvement in approximately 70–80% of patients (Cortese, 2020).

    Multiple Formulations:
     Available in immediate-release (short-acting) and extended-release (long-acting) forms, allowing flexibility based on patient needs.

    Rapid Onset:
     Symptom relief can begin 30–60 minutes after administration.

    Disadvantages:

     
    Potential for Abuse and Dependence:
     Amphetamines are Schedule II controlled substances, meaning they have a high potential for misuse.

    Side Effects:
     Common side effects include insomnia, appetite suppression, increased heart rate, and potential anxiety.

    Shorter Duration (Immediate-Release Forms):
     Requires multiple daily dosing, which may lead to fluctuating symptom control.

     
    Comparison to Non-Stimulant Medications

    Non-stimulant medications, such as atomoxetine (a selective norepinephrine reuptake inhibitor), provide an alternative with lower abuse potential. However, they often take several weeks to achieve full therapeutic effects and may be less effective than stimulants in some patients (Spencer et al., 2020). Non-stimulants may be preferable for patients with substance use concerns or significant side effects from stimulants.

     
    Potential Side Effects and Considerations

     
     Consideration:
     Due to the potential for misuse, strict prescribing regulations apply to amphetamines, requiring careful monitoring and adherence to state and federal laws. 
    Example: A prescriber must use Prescription Drug Monitoring Programs (PDMPs) to track controlled substance prescriptions.

     
    Ethical Consideration:
     Physicians must balance the benefits of stimulant therapy with the risk of misuse, ensuring the medication is prescribed for legitimate medical purposes. 
    Example: Assessing a patient’s history of substance abuse before prescribing amphetamines.

     
    Social Consideration:
     ADHD stigma may affect patients’ willingness to seek treatment or disclose their condition at work. 
    Example: Jessica may face workplace bias, leading her to feel hesitant about disclosing her ADHD diagnosis to her employer.

     

     
    References

    Arnsten, A. F., & Rubia, K. (2012). Neurobiological circuits regulating attention, cognitive control, and impulsivity: Implications for ADHD. 
    Neuropsychopharmacology
    , 
    38
    (1), 196-206. https://doi.org/10.1038/npp.2012.104

    Biederman, J., Spencer, T. J., & Faraone, S. V. (2019). Evidence-based pharmacologic management of attention-deficit hyperactivity disorder. 
    The International Journal of Neuropsychopharmacology, 22
    (3), 168-180.

    Biederman, J., Spencer, T. J., Monuteaux, M. C., & Faraone, S. V. (2019). A naturalistic study of once-daily mixed amphetamine salts and osmotic-release oral system methylphenidate in children with ADHD. 
    Journal of Attention Disorders
    , 
    23
    (5), 518-526. https://doi.org/10.1177/1087054717690818

    Cortese, S. (2020). Pharmacologic treatment of attention deficit–hyperactivity disorder. 
    The New England Journal of Medicine, 383
    (11), 1050-1056.

    Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., & Cipriani, A. (2020). Comparative efficacy and tolerability of medications for ADHD in children, adolescents, and adults: A systematic review and network meta-analysis. 
    The Lancet Psychiatry
    , 
    7
    (9), 741-750. https://doi.org/10.1016/S2215-0366(20)30269-4

    Spencer, T. J., Brown, A., Seidman, L. J., & Biederman, J. (2020). Non-stimulant treatments for adult ADHD. 
    The Journal of Clinical Psychiatry, 81
    (5), 19m13153.Volkow, N. D., Wang, G. J., Tomasi, D., & Baler, R. D. (2021). Unraveling the complexity of attention-deficit/hyperactivity disorder: The role of dopamine and other neurotransmitters. 
    Biological Psychiatry, 89
    (5), 497-508.

    Storebø, O. J., Ramstad, E., Krogh, H. B., Nilausen, T. D., Skoog, M., Rosendal, S., … & Simonsen, E. (2018). Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents. 
    The Cochrane Database of Systematic Reviews
    , 
    2018
    (8). https://doi.org/10.1002/14651858.CD009885.pub2

    Volkow, N. D., Wang, G. J., Tomasi, D., & Baler, R. D. (2021). Unraveling the complexity of attention-deficit/hyperactivity disorder: The role of dopamine and other neurotransmitters. 
    Biological Psychiatry, 89
    (5), 497-508.

    Expand discussion thread from Emmanuel C Ezeala

    2 Replies, 2 Unread

    2 Replies, 2 Unread

    Reply to post from Emmanuel C Ezeala
    Reply

    Mark as Unread
    Mark as Unread

    HB

    Honorine Berewoudougou

    Apr 2, 2025 2:04am
    | Last reply Apr 5, 2025 8:47pm

    Reply from Honorine Berewoudougou

     

    MAIN POST

    Most of the time, selecting medications to treat ADHD and other psychological disorders is usually between stimulants such as Amphetamine and Methylphenidate. According to Liu et al., 2008, Current medications for the management of ADHD are primarily aimed at regulating brain dopamine and/or norepinephrine levels. The most effective and frequently prescribed drug for ADHD, methylphenidate, is a psychostimulant that inhibits reuptake and stimulates the release of dopamine in the central nervous system, thereby increasing the temporal and spatial presence of dopamine at post-synaptic receptors.

    Patients 1 and 2

    In these cases, the choice of the medication is critical due to the patient’s age. The two classes of medications to consider are the stimulants as well as the alternative, the Adrenergic Agonists, and non-stimulants. These two classes of medication come with distinct advantages and potential drawbacks. “Neurotransmitter transporters at the plasma membrane contribute to the clearance and recycling of neurotransmitters and profoundly impact the extent of receptor activation during neuronal signaling. These carriers are also the primary targets for psychostimulant drugs of abuse, antidepressant medications, and drugs such as methylphenidate and amphetamines, which are used to treat attention deficit disorders in children. In recent studies, we have observed that once amphetamine-like drugs enter dopamine neurons, they activate multiple intracellular signaling pathways to trigger changes in the cellular trafficking of the dopamine transporter and other neuronal membrane proteins. Within the cell, amphetamines activate the small GTPases Rho and Rac1, triggering the dopamine transporter (DAT) endocytosis by a RhoA- and dynamin-dependent pathway” (Amara, 2013).

    These two patients will benefit from the stimulant because stimulants are proven to be effective for ADHD or narcolepsy because they are great at managing inattention, impulsivity, and hyperactivity.

    The advantage of the stimulants is their rapid effect on helping a patient with their symptoms. There are numerous types of research done that support the efficacity of stimulants regarding the management of ADHD and narcolepsy. According to Jordan et al., 2016, non-stimulant medications are not as clinically efficacious as methylphenidate for ADHD symptoms.

    Dexedrine, Adderall, and Vyvanse are the three most commonly prescribed amphetamine formulations for ADHD worldwide. This makes stimulants the first line of treatment for ADHD. For Boles et al., 2001, There have been substantial increases in the use of methylphenidate and other psychotropic drugs in the treatment of ADHD. Most children with ADHD receive psychostimulants, with methylphenidate being the most frequently prescribed. Numerous studies have documented the safety, efficacy, and tolerability of these agents in children with ADHD. Over 70% of patients are successfully treated with stimulants in the short term.

    The disadvantages of stimulants are the side effects, tolerability, dependence, and misuse.  The side effects are loss of appetite, insomnia, headache, abdominal pain, weight loss, vomiting, tachycardia, dry mouth, nausea, and dizziness. Long-term use of the medication can lead to problems with tolerance and dependence. Also, stimulants can be misused easily and diverted, which will create serious health problems or conditions.

    “This medication has a high potential for abuse and misuse, which can lead to the development of substance use disorder, including addiction; misuse and abuse of CNS stimulants can result in overdose and death, and this Risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing this medication, assess each patient’s Risk for abuse, misuse, and addiction; educate patients and their families about risks, proper storage of the drug, and proper disposal of any unused drug. Throughout treatment, reassess each patient’s Risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction. Also, in women exposed during pregnancy, healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychostimulants at 1-866-961-2388 or visiting online at 
    https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/othermedications/
    Links to an external site.
    ” (Medscape).

    On the other hand, Alpha Adrenergic Agonist nonstimulants work differently. According to Liu et al., 2008, a non-stimulant drug has also been widely employed in the treatment of ADHD. The reduction of ADHD symptoms by stimulants is probably associated with norepinephrine and dopamine levels in the prefrontal cortex (PFC) and their effects on attention, arousal, and cognition. These processes may be mediated by activating the norepinephrine α-2 and/or dopamine D1 receptors. They are not addictive or abused like stimulants and generally have a lower side effect and more extended management, which makes them a potential option for children and adolescents who are considered as advantages. According to Boles et al., 2001, Although stimulants are the most established treatment for ADHD, up to 30% of patients either do not respond sufficiently to stimulants or do not tolerate them. Non-stimulant medications, such as antidepressants, alpha-adrenergic agonists, and neuroleptics, have been tried in cases where psychostimulants were ineffective, not tolerated by patients, or unacceptable to parents.

    Unfortunately, they are less effective in the treatment of ADHD than stimulants and may take longer to see a therapeutic response or effects, which is a disadvantage. ADHD is challenging to treat as regard of selecting the perfect class of medication due to the other psychiatric disorders that accompanied ADHD. The side effects are Drowsiness, fatigue, dry mouth, and constipation. According to Medscape, avoid abrupt withdrawal (it can result in anxiety, nervousness, and rebound hypertension). It may cause hypotension, orthostasis, bradycardia, and syncope; use with caution in a history of cerebrovascular disease, recent MI, severe coronary insufficiency, or syncope. Chronic renal/hepatic failure May cause sedation, especially at the start; avoid operating heavy machinery. Skin rash with exfoliation reported. Avoid concomitant use with other CNS depressants as they may potentiate CNS effects. The Risk of cardiovascular effects may increase when administered concurrently with antihypertensive medications or drugs that affect heart rate.

    Legal

    Prescription and dispensing of controlled substances as stimulants are significantly and carefully regulated. Misuse and diversion of the stimulant can pose legal consequences.

    Ethical

    The ethical consideration regarding the stimulant is to proceed with carefulness due to the high potential of abuse and misuse, which in turn can create more health issues than healing the patient. Nurse practitioners must ensure that the prescribed medication is used correctly based on the patient’s diagnosis and emphasize educating the patient on the risks and benefits.

    Social

    The social part of ADHD medication use is the increasing situation of mental health patients using stimulants and the possible Risk of misuse or diversion within the communities.

     

    Both patients will benefit from the stimulants as the first choice, but they require monitoring and a lot of education. In case of tolerability issues, misuse, or dependence, the patients can be switched to stimulants, Alpha Adrenergic Agonist. Both medications can be given orally, and some medications within those two classes can be extended-release.

     

    Amara, S. G. (2013). A new take on uptake: neurotransmitter transporters and the cellular mechanisms of amphetamine action. 
    Proceedings of the Physiological Society
    , 219P–220P.

    Boles, M., Lynch, F. L., & DeBar, L. L. (2001). Variations in pharmacotherapy for attention deficit hyperactivity disorder in managed care. 
    Journal of Child and Adolescent Psychopharmacology
    , 
    11
    (1), 43–52. https://doi.org/10.1089/104454601750143429

    https://reference.medscape.com/drug/adderall-mydayis-amphetamine-dextroamphetamine-342997#3

    Jordan, C., Lemay, C., Dwoskin, L., & Kantak, K. (2016). Adolescent d-amphetamine treatment in a rodent model of attention deficit/hyperactivity disorder: impact on cocaine abuse vulnerability in adulthood. 
    Psychopharmacology
    , 
    233
    (23/24), 3891–3903. https://doi.org/10.1007/s00213-016-4419-2

    Liu, L.-L., Yang, J., Lei, G.-F., Wang, G.-J., Wang, Y.-W., & Sun, R.-P. (2008). Atomoxetine Increases Histamine Release and Improves Learning Deficits in an Animal Model of Attention-Deficit Hyperactivity Disorder: The Spontaneously Hypertensive Rat. 
    Basic & Clinical Pharmacology & Toxicology
    , 
    102
    (6), 527–532.

     

    Expand discussion thread from Honorine Berewoudougou

    1 Reply, 1 Unread

    1 Reply, 1 Unread

    Reply to post from Honorine Berewoudougou
    Reply

    Mark as Unread
    Mark as Unread

    Moreen Bibi

    Apr 1, 2025 11:12pm
    | Last reply Apr 3, 2025 10:02pm

    Reply from Moreen Bibi

    Main Post
    ADHD Medication Debate Discussion

    Medicine Classes That Have Been Selected:

    Pro: Methylphenidate

    Con: Alpha-adrenergic agonist

    The mechanism of action and the patients’ appropriateness

    Methylphenidate (Pro) Methylphenidate is a central nervous system (CNS) stimulant that inhibits the reuptake of dopamine and norepinephrine, thereby increasing their levels in the brain. This results in improved attention, impulse control, and reduced hyperactivity. Due to its rapid onset and efficacy in treating the primary symptoms of ADHD, such as hyperactivity, impulsivity, and inattention, methylphenidate is suitable for both Malcolm and Jessica (Storebø et al., 2018).

    Alpha Adrenergic Agonist (Con) The prefrontal cortex is stimulated by alpha-2 receptors by alpha adrenergic agonists, such as clonidine or guanfacine, resulting in reduced norepinephrine release and the modulation of attention and impulse control (Arnsten, 2017). These medications are frequently prescribed for ADHD patients who have coexisting conditions, such as anxiety or sleep disturbances. However, their efficacy in alleviating central ADHD symptoms is generally inferior to that of stimulants.

    Benefits and Drawbacks

    Methylphenidate (Pro)

    Benefits:

    Fast-acting, with effects typically manifesting within 30-60 minutes.

    Formulations are available in both immediate-release and extended-release forms.

    Demonstrated effectiveness in the reduction of ADHD symptoms in both infants and adults.

    It can be customized to meet the specific requirements of each individual through dosage adjustments.

    List of disadvantages:

    Due to its stimulant properties, there is a risk of misuse or dependence.

    Appetite suppression, sleep disturbances, and an elevated heart rate may result.

    Unsuitable for patients with a history of substance addiction or significant cardiovascular conditions.

    Alpha Adrenergic Agonist (Con)

    Benefits:

    Non-stimulant, which minimizes the likelihood of dependence or misconduct.

    It can be advantageous for patients with ADHD who suffer from anxiety or sleep disorders.

    Significant appetite suppression is less probable.

    List of disadvantages:

    Fatigue and sedation are frequent adverse effects.

    In comparison to stimulants, the onset of action is delayed.

    Less effective in the treatment of core ADHD symptoms, including hyperactivity and inattention.

    Comparison of Alternative Medication Options

    Amphetamines: A stimulant class that is similar to methylphenidate, but may be associated with a greater risk of dependence and cardiovascular adverse effects.

    Non-stimulants, such as Atomoxetine, are beneficial for patients who have contraindications to stimulants. However, they have a delayed onset (weeks) and the potential for mood-related adverse effects.

    Adverse Effects and Factors to Consider

    Methylphenidate: Potential for misuse, weight loss, insomnia, and increased heart rate.

    Alpha Adrenergic Agonists: Fatigue, drowsiness, and potential withdrawal symptoms may occur upon discontinuation.

    Social, Ethical, and Legal Consequences

    Legal Consideration: Methylphenidate is classified as a Schedule II controlled substance, necessitating meticulous prescribing and monitoring to prevent diversion and abuse (Drug Enforcement Administration, 2021).

    Ethical Consideration: When prescribing stimulant medications, prescribers must ensure informed consent and balance the risk of dependency with effective symptom management.

    Social Consideration: Stimulants such as methylphenidate may be associated with a stigma, which could potentially impact their self-perception and workplace interactions, particularly for adults like Jessica.

    In conclusion,

    Methylphenidate is a highly effective first-line treatment for ADHD, particularly for patients who require immediate symptom control. Alpha adrenergic agonists may not be as effective in managing central ADHD symptoms, despite the fact that they offer an alternative for individuals with stimulant intolerance or sleep disturbances. Methylphenidate is likely the preferable option to mitigate risks, given the significant functional impairments in both Malcolm and Jessica. However, meticulous monitoring is required.

    References

    Arnsten, A. F. T. (2017). The neurobiology of ADHD: Catecholamine influences on prefrontal cortical function. 
    Molecular Psychiatry, 22
    (1), 5-15.

    Drug Enforcement Administration. (2021). Controlled substances schedules. Retrieved from 
    https://www.dea.gov/drug-information/drug-scheduling

    Storebø, O. J., Krogh, H. B., Ramstad, E., Moreira-Maia, C. R., Holmskov, M., Skoog, M., … & Gluud, C. (2018). Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents–assessment of adverse events in non-randomised studies. 
    Cochrane Database of Systematic Reviews, 2018
    (5).

    Expand discussion thread from Moreen Bibi

    3 Replies, 3 Unread

    3 Replies, 3 Unread

    Reply to post from Moreen Bibi
    Reply

    Mark as Unread
    Mark as Unread

    CE

    Courtney Ekhator

    Apr 1, 2025 10:33pm
    | Last reply Apr 3, 2025 7:06pm

    Reply from Courtney Ekhator

    Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental condition that affects both children and adults, impacting daily functioning, academic achievement, and interpersonal relationships. Pharmacologic treatment remains a key component of symptom management. This post explores the pros and cons of two medication classes—amphetamines and alpha adrenergic agonists—by evaluating their use in two distinct patient profiles: a school-aged child, Malcolm, and an adult, Jessica.

    1. Mechanism of Action and Clinical Use

    Amphetamines
    Amphetamines function by boosting the levels of dopamine and norepinephrine in the brain through increased release and reuptake inhibition. This action improves attention, focus, and behavioral control, making them highly effective for both children and adults diagnosed with ADHD (Stahl, 2021). For Malcolm, who displays hyperactivity and impulsivity, and Jessica, who struggles with distractibility and workplace challenges, amphetamines offer targeted symptom relief.

    Alpha Adrenergic Agonists
    Agents like guanfacine and clonidine activate alpha-2A adrenergic receptors in the prefrontal cortex, which helps regulate emotional and behavioral responses by modulating norepinephrine signaling (Stahl, 2021). These medications are typically more effective for hyperactivity and sleep-related disturbances, making them a viable option for children like Malcolm who have difficulty with aggression or sleep, though they are not commonly used in adults like Jessica.

    2. Benefits and Limitations

    Amphetamines – Strengths

    Available in both short-acting and extended-release formulations for flexible dosing.

    Rapid onset and strong evidence base supporting efficacy in both pediatric and adult ADHD.

    Once-daily dosing with extended-release forms enhances convenience and compliance (Goldin, 2023).

    Amphetamines – Drawbacks

    May cause appetite loss, trouble sleeping, or anxiety.

    Carry a higher risk of misuse or diversion, especially in older patients.

    Can raise heart rate and blood pressure, requiring cardiovascular monitoring.

    Alpha Adrenergic Agonists – Strengths

    Non-stimulant class with low abuse potential.

    Useful for managing symptoms like impulsivity, aggression, and sleep problems.

    Often used when stimulants are contraindicated or poorly tolerated.

    Alpha Adrenergic Agonists – Drawbacks

    Less effective for attention-related symptoms, especially in adults.

    Slower onset and more limited effect on overall cognitive performance.

    Side effects may include sedation, low blood pressure, and fatigue (Stahl, 2021).

    3. Comparison Between Classes

    Amphetamines provide a broader range of symptom relief and are often considered the first-line treatment for both children and adults with ADHD (American Academy of Pediatrics [AAP], 2019). In contrast, alpha adrenergic agonists are more specialized and are typically reserved for individuals who do not tolerate stimulants well, particularly children with behavioral outbursts or sleep disturbances. For Jessica, the effectiveness of amphetamines in reducing distractibility and improving executive function is likely to outweigh the benefits of alpha agonists.

    4. Side Effects and Clinical Monitoring

    Amphetamines
    Common adverse effects include reduced appetite, difficulty sleeping, and mood changes. There are also potential cardiovascular concerns that require monitoring. Additionally, the potential for substance misuse necessitates caution, especially in adults (CHADD, 2023).

    Alpha Adrenergic Agonists
    Patients may experience drowsiness, dizziness, and low blood pressure. Abrupt discontinuation can lead to rebound hypertension, making careful dose tapering necessary (Goldin, 2023).

    5. Legal, Ethical, and Social Factors

    Legal Consideration (Amphetamines):
    Due to their classification as Schedule II controlled substances, strict prescribing laws apply. Clinicians must document treatment rationale and monitor for misuse.

    Ethical Consideration (Alpha Agonists):
    Providers should consider if choosing a less effective medication solely to avoid stimulant risks might compromise treatment outcomes, especially in adults who require improved concentration.

    Social Consideration (Amphetamines):
    Adults like Jessica may encounter social stigma or workplace concerns surrounding stimulant use, which could impact adherence. Transparent discussion and education are essential to mitigate misunderstanding.

    Conclusion
    Amphetamines remain the gold standard for ADHD due to their strong efficacy profile and rapid onset of action. They are well-suited for both Jessica and Malcolm when benefits outweigh risks. Alpha adrenergic agonists may be preferred for Malcolm if stimulant side effects or comorbid issues like sleep disturbances arise. As always, treatment must be personalized, balancing symptom control, tolerability, patient preferences, and broader psychosocial factors.

    References

    American Academy of Pediatrics. (2019). 
    Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents
    . 
    Pediatrics, 144
    (4), e20192528. 
    https://doi.org/10.1542/peds.2019-2528
    Links to an external site.

    CHADD’s National Resource Center on ADHD. (2023). 
    ADHD medications approved by the U.S. Food and Drug Administration: Stimulant medications
    . 
    https://d393uh8gb46l22.cloudfront.net/wp-content/uploads/2020/02/ADHD-Medications-Approved-by-FDA-2.23.pdf
    Links to an external site.

    Goldin, D. S. (2023). 
    Fast facts for psychopharmacology for nurse practitioners
    . Springer Publishing.

    Stahl, S. M. (2021). 
    Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications
     (5th ed.). Cambridge University Press.

    Expand discussion thread from Courtney Ekhator

    1 Reply, 1 Unread

    1 Reply, 1 Unread

    Reply to post from Courtney Ekhator
    Reply

    Mark as Unread
    Mark as Unread

    IG

    Ingrid Marianne Gamboa

    Apr 1, 2025 10:09pm
    | Last reply Apr 4, 2025 11:45am

    Reply from Ingrid Marianne Gamboa

    Discussion week 6

      Patient 1

    Medication; Methylphenidate

    Methylphenidate stimulates the central nervous system, inhibiting the brain’s reuptake of dopamine and norepinephrine, increasing their availability in the synaptic cleft. This enhances neurotransmission in attention and impulse control.

    Why is it appropriate:

    In the first case, which refers to a 9-year-old with ADHD, methylphenidate will help decrease hyperactivity and impulsiveness and improve focus. It will also allow him to complete tasks such as homework, which could lead to better behavior in school and at home.

    Benefits of  Methylphenidate

    Fast onset of action: Many formulations begin working within 30-60 minutes. Available on immediate-release (IR), extended-release (ER), and long-acting options which decrease the need to re-dose at school.

    Methylphenidate has been in the market for a long period so is a well-known medication. Methylphenidate will help Malcolm improve focus and attention span, reduce distractibility and increase task completion.

    Methylphenidate can also improve behavioral concerns as it decreases impulsive behavior and hyperactivity.

    Methylphenidate disadvantages.

    May need titration: Finding the correct dose often requires adjustment.

    Appetite suppression: Malcolm is a 9 y/o that is still in the growing process. By suppressing the appetite this can lead to poor weight gain or growth delays, particularly in children.  Some patients may experience insomnia and irritability or mood swings:  especially when medication is wearing off.

    Side effects to monitor will include periodic monitoring of height, weight, blood pressure, and heart rate.

    Legal, Ethical, and Social Implications; Methylphenidate is a Schedule II controlled substance, requiring careful prescribing, monitoring, and secure storage. For Malcolm, regular follow-ups are essential.

       Case 2

    Medication; Amphetamine

    Amphetamine mechanism of action

    Amphetamines increase the release of dopamine and norepinephrine from presynaptic neurons and also interfere their reuptake, resulting in greater neurotransmitter availability in the prefrontal cortex and other brain regions associated with attention and executive function.

    Why is medication appropriate for this patient?

    The patient is struggling with completing tasks, the patient gets easily distracted, and suffers from impulsive behavior at work, amphetamines help to enhance attention, productivity, and reduce bein easily distracted. Successful treatment can drastically improve her confidence, workplace productivity, and interpersonal relationships.

    Advantages of Amphetamine

     Longer duration of action: Especially with extended-release formulations like Vyvanse, which can last 10–14 hours.

      Consistent symptom relief: Helps improve organizational function, emotional regulation, and time management.

      Combination of formulations: Available in short-acting, intermediate, and long-acting.

      Efficacy in adults: Amphetamines are highly effective for ADHD treatment with longstanding supporting evidence.

    Disadvantages Compared to Other Medication Options

      Higher abuse potential: Amphetamines has a high risk of misuse and dependence compare to non-stimulants such as atomoxetine.

      Patients may experience irritability when the medication wears off.

       Greater cardiovascular effects: Stimulants can cause tachycardia and increase blood pressure.

      Accessibility; High demand leads to the medication being backorder. A patient may experience difficulty obtaining their prescriptions or refills as it is a stimulant Schedule II classification.

    Side Effects

       Appetite suppression: May lead to weight loss or delayed growth in pediatrics, insomnia, Anxiety, mood swings, and dependence

    Legal, Ethical, and Social Implications

     Legal Implications: Amphetamines are Schedule II controlled substances. Prescribers must assess for misuse, and use prescription monitoring programs (PMPs). Patients must adhere to prescribed guidelines.

     Ethical: Accurate diagnosis is critical. It would be unethical to prescribe just to improve performance without clear diagnosis. Patient was properly diagnosed by a psychologist, suporting the ethical decision to treat.

      Social: There may be hesitance from some providers to prescribe ADHD stimulants. The patient might want to withhold the current diagnosis from coworkers and supervisors.

    References

    D’Aiello, B., Gessi, L., Menghini, D., Vicari, S., & De Rossi, P. (2025). Sleep disturbances in children with adhd on methylphenidate monotherapy: The role of dysregulation profile. 
    Sleep Medicine
    , 
    128
    , 153–158. Retrieved April 1, 2025, from 
    https://doi.org/10.1016/j.sleep.2025.02.001
    Links to an external site.

    Drugs.com. (2025a, March 12). 
    Amphetamine
    . Retrieved April 1, 2025, from 
    https://www.drugs.com/search.php?searchterm=amphetamine&a=1
    Links to an external site.

    Drugs.com. (2025b, March 12). 
    Methylphenidate
    . Retrieved April 1, 2025, from 
    https://www.drugs.com/search.php?searchterm=methylphenidate&a=1
    Links to an external site.

    Shang, C. Y., Yan, C. G., Lin, H. Y., Tseng, W. Y., Castellanos, F. X., & Gau, S. S. (2016). Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder. 
    Psychological Medicine
    , 
    46
    (15), 3173–3185. Retrieved April 1, 2025, from 
    https://doi.org/10.1017/s0033291716001938
    Links to an external site.

    Wu, L., Zhao, D., Lan, Y., Jin, L., & Yang, L. (2025). Comparison of serious adverse effects of methylphenidate, atomoxetine and amphetamine in the treatment of adhd: An adverse event analysis based on the faers database. 
    BMC Pharmacology and Toxicology
    , 
    26
    (1). Retrieved April 1, 2025, from 
    https://doi.org/10.1186/s40360-025-00868-5
    Links to an external site.

     

     

    Expand discussion thread from Ingrid Marianne Gamboa

    1 Reply, 1 Unread

    1 Reply, 1 Unread

    Reply to post from Ingrid Marianne Gamboa
    Reply

    Mark as Unread
    Mark as Unread

    LI

    Linda Idi

    Apr 1, 2025 6:58pm
    | Last reply Apr 7, 2025 8:52am

    Reply from Linda Idi

    Hello, professor and class,

    In this discussion, I will compare the medication classes of amphetamines and non-stimulants for the treatment of ADHD in two patients: Malcolm, a 9-year-old child, and Jessica, a 32-year-old adult. I will outline the pros and cons of these medication options by considering their mechanisms of action, advantages and disadvantages, side effects, and potential legal, ethical, and social implications.

    Patient 1: Malcolm (9-Year-Old Male)

    Malcolm is a 9-year-old male diagnosed with attention deficit hyperactivity disorder (ADHD), exhibiting symptoms of hyperactivity, impulsivity, and inattention. He encounters challenges in the educational environment, such as interrupting during lessons, leaving his seat, and engaging in physical altercations with peers. At home, he struggles to complete household chores and is easily distracted. These behaviors align with the characteristics of combined presentation ADHD. Given these symptoms, it is imperative to evaluate pharmacological treatment options, specifically amphetamines and non-stimulants.

    Amphetamines

    Mechanism of Action
    : Amphetamines, including medications such as Adderall and Vyvanse, function by increasing the levels of norepinephrine and dopamine in the brain, particularly within regions responsible for attention and impulse control. For Malcolm, who primarily experiences challenges associated with hyperactivity and impulsivity, the stimulant properties of amphetamines can significantly enhance his concentration and reduce impulsive behaviors (Faraone et al., 2024).

    Advantages for Malcolm:

    Efficacy: Stimulants
    , such as Adderall, are frequently the first-line treatment for children diagnosed with ADHD, owing to their established efficacy in improving both attention deficits and hyperactive behaviors (Hartz et al., 2024). This is particularly relevant for addressing Malcolm’s difficulties in a school setting, including interruptions and inability to remain seated.

    Rapid Onset: 
    These medications demonstrate a quick onset of action, typically within 30 minutes, providing immediate therapeutic effects that can benefit Malcolm during critical situations, such as academic instruction or homework completion.

    Disadvantages for Malcolm:

    Side Effects: 
    Common adverse effects associated with amphetamines in pediatric populations include appetite suppression, sleep disturbances, and potential increases in anxiety or irritability (Weibel et al., 2020). Given Malcolm’s existing challenges with focus and frustration, these side effects may exacerbate his mood or result in difficulties with eating and sleeping.

    Misuse Concerns
    : Although misuse is generally not a significant concern for young children, long-term use of stimulants can carry a risk of dependence as they mature. It is essential to monitor Malcolm’s medication as he grows older to prevent potential misuse, either personally or among peers.

    Legal, Ethical, and Social Considerations:

    Legal: 
    The prescription of amphetamines for children is subject to regulatory scrutiny; hence, healthcare providers must exercise caution regarding accurate diagnosis and monitoring procedures. Parental consent and ongoing supervision are essential to ensure appropriate medication utilization in Malcolm’s case.

    Ethical: 
    It is ethically critical to ensure that Malcolm’s parents are thoroughly informed about the potential side effects and risks associated with the medication, particularly concerning long-term implications. Additionally, it is advisable to discuss behavioral therapy as a complementary treatment approach.

    Social: 
    There may be societal stigma associated with the use of stimulant medications in educational environments. Peers may lack understanding of ADHD and the rationale for medication use, thereby creating potential social challenges for Malcolm.

    Non-Stimulants:

    Mechanism of Action: 
    Non-stimulant medications, such as atomoxetine (Strattera), operate by selectively inhibiting the reuptake of norepinephrine in the brain. This mechanism improves attention without the stimulant effects on dopamine, which renders it less likely to induce anxiety or sleep disturbances (Hartz et al., 2024).

    Advantages for Malcolm:

    Fewer Side Effects: 
    Non-stimulant medications are generally associated with a lower incidence of appetite suppression and sleep disruptions, a significant advantage for Malcolm, given his existing behavioral challenges and possible mood issues.

    Reduced Risk of Misuse: 
    Non-stimulants possess no potential for abuse, making them a safer option for prolonged use in children such as Malcolm, mitigating the risk of stimulant misuse in the future.

    Disadvantages for Malcolm:

    Slower Onset: 
    In contrast to stimulants, non-stimulants may require several weeks to achieve their full therapeutic effect, which could be less advantageous for Malcolm, who necessitates more immediate symptom relief, particularly in academic settings (Weibel et al., 2020).

    Lower Efficacy: 
    Non-stimulants may not demonstrate the same level of effectiveness in addressing both hyperactivity and inattention when compared to stimulants. This may result in less efficacy in managing Malcolm’s combined ADHD symptoms (Schein et al., 2023).

    Legal, Ethical, and Social Considerations:

    Legal: While
     the prescription of non-stimulants is generally less regulated, healthcare providers must ensure that the diagnosis is accurate and that Malcolm’s condition warrants the use of a non-stimulant medication.

    Ethical: 
    Healthcare providers must ensure that parents are fully informed regarding the medication’s risks and benefits, as well as provide ongoing monitoring and behavioral interventions required to enhance Malcolm’s treatment outcomes.

    Social: 
    Since atomoxetine does not carry the same stigma associated with stimulant medications, Malcolm may experience reduced social pressure or bullying within the school environment, which may alleviate anxiety related to his medication use
    .

     

    Patient 2: Jessica’s ADHD Challenges and Medication Options

    Jessica is an adult diagnosed with ADHD who struggles with distractibility, impulsiveness, and completing tasks at work. She frequently engages in conversations with colleagues, which makes it difficult for her to stay on task and has negatively impacted on her performance and interpersonal relationships. Both stimulant and non-stimulant medication options should be considered for Jessica.

    Amphetamines

    Advantages for Jessica:

    Efficacy:
     Stimulants such as Adderall or Vyvanse are effective in improving attention and reducing impulsivity, addressing Jessica’s challenges at work. These medications can help her maintain focus and complete tasks, potentially enhancing her job performance (Schein et al., 2023).

    Rapid Action
    : These medications have a quick onset of action, allowing Jessica to experience relief from distractibility during work hours, which can be advantageous in a professional setting.

    Disadvantages for Jessica:

    Side Effects
    : Common side effects, such as increased anxiety, jitteriness, or insomnia, may interfere with Jessica’s work performance and overall well-being (Weibel et al., 2020). Managing these side effects in a professional environment can be challenging for adults.

    Risk of Misuse
    : Although the risk of misuse is less significant in adults compared to adolescents, there is still a potential concern, especially if Jessica has a history of substance abuse (Schein et al., 2023). Access to stimulants without proper oversight could exacerbate this issue.

    Legal, Ethical, and Social Considerations:

    Legal:
     The prescription of amphetamines for ADHD is regulated, and Jessica’s provider must ensure that her diagnosis is well-supported by psychological evaluations. Additionally, workplace drug testing may complicate matters if Jessica is subject to such screenings.

    Ethical
    : Ethical considerations include ensuring Jessica’s informed consent and weighing the potential benefits and risks of stimulant use, including the management of side effects in a professional environment.

    Social:
     Jessica may face stigma at work due to her medication use, particularly in a professional environment where colleagues might view it negatively. This could lead to feelings of social isolation or misunderstanding.

    Non-Stimulants:

    Advantages for Jessica:

    Lower Risk of Abuse: Non-stimulants like atomoxetine (Strattera) are not addictive, which is beneficial if Jessica has concerns about misuse or substance dependency (Hartz et al., 2024).

    Fewer Side Effects
    : Non-stimulants typically have fewer side effects related to anxiety or sleep disturbances, which could be advantageous for Jessica, especially if she has a history of stress or difficulty managing sleep.

    Disadvantages for Jessica:

    Slower Onset:
     Non-stimulants have a slower onset of action and may take several weeks to show full effectiveness, which might not provide immediate relief for Jessica’s workplace challenges (Hartz et al., 2024).

    Efficacy:
     Non-stimulants may not be as effective as stimulants in reducing impulsiveness or improving attention, potentially leaving Jessica with some residual ADHD symptoms, especially in a fast-paced work environment (Schein et al., 2023).

    Legal, Ethical, and Social Considerations:

    Legal:
     Similar to stimulant medications, the prescription of non-stimulants should be thoroughly documented, especially if Jessica is subject to workplace drug testing.

    Ethical:
     Jessica’s provider must ensure she understands the implications of long-term medication use and any potential side effects. Informed consent is essential, particularly if any work-related issues arise due to the medication.

    Social:
     Non-stimulants might have a lower stigma associated with them when it comes to ADHD treatment, which could help reduce potential workplace stigma. However, Jessica may still find it challenging to discuss her condition with coworkers.

    Conclusion

    Both medication options, of amphetamines and non-stimulants, have their advantages and disadvantages based on individual needs. For individuals who require immediate symptom control and have significant hyperactivity, amphetamines may be the most suitable option, although careful monitoring of side effects is essential. For Jessica, who is looking for a solution to her ADHD symptoms as an adult, non-stimulants may provide a safer long-term option with fewer side effects despite their slower onset. Ultimately, treatment must be tailored to the individual, taking into account both medical and social factors.

    References:

    Hartz, I., Madsstuen, N. H. H., Andersen, P. N., Handal, M., & Odsbu, I. (2024, November 5). Nationwide trends in the use of ADHD medications in the period 2006-2022: A study from the Norwegian prescription database. 
    BMC Psychiatry, 24
    (1), 767. 
    https://doi.org/10.1186/s12888-024-06199-9
    Links to an external site.

    Faraone, S. V., Bellgrove, M. A., Brikell, I., Cortese, S., Hartman, C. A., Hollis, C., Newcorn, J. H., Philipsen, A., Polanczyk, G. V., Rubia, K., Sibley, M. H., & Buitelaar, J. K. (2024, February 22). Attention-deficit/hyperactivity disorder. 
    Nature Reviews Disease Primers, 10
    (1), 11. 
    https://doi.org/10.1038/s41572-024-00495-0
    Links to an external site.

    Weibel, S., Menard, O., Ionita, A., Boumendjel, M., Cabelguen, C., Kraemer, C., Micoulaud-Franchi, J. A., Bioulac, S., Perroud, N., Sauvaget, A., Carton, L., Gachet, M., & Lopez, R. (2020, February). Practical considerations for the evaluation and management of Attention Deficit Hyperactivity Disorder (ADHD) in adults. 
    Encephale, 46
    (1), 30-40. 
    https://doi.org/10.1016/j.encep.2019.06.005
    Links to an external site.

    Schein, J., Cloutier, M., Gauthier-Loiselle, M., Bungay, R., Arpin, E., Guerin, A., & Childress, A. (2023, November 23). Risk factors associated with newly diagnosed attention-deficit/hyperactivity disorder in adults: A retrospective case-control study. 
    BMC Psychiatry, 23
    (1), 870. https://doi.org/10.1186/s12888-023-05359-7

     

    Expand discussion thread from Linda Idi

    1 Reply, 1 Unread

    1 Reply, 1 Unread

    Reply to post from Linda Idi
    Reply

    Mark as Unread
    Mark as Unread

    NH

    Natasha Hurley

    Apr 1, 2025 4:17pm
    | Last reply Apr 5, 2025 2:17pm

    Reply from Natasha Hurley

    Throughout this discussion, I will present my arguments regarding medication use for Attention Deficit Hyperactivity Disorder (ADHD) treatment between Stimulants (Amphetamine and Methylphenidate) and Non-stimulants. The analysis includes evaluation of medicinal advantages and drawbacks for two ADHD patients named Malcolm who is a 9-year-old male and Jessica who is a 32-year-old female.

    Pro: Stimulants (Amphetamine and Methylphenidate)

    Mechanism of Action
    : Stimulant medications based on amphetamines together with methylphenidate cause the brain to increase the availability of neurotransmitters dopamine and norepinephrine. Increased neurotransmitters allow patients with ADHD to achieve better attention span and enhanced focus and reduced impulsive behavior (Banaschewski et al., 2017). Both Malcolm and Jessica need stimulant medication as a treatment to handle daily activities affected by their ADHD characteristics, including homework completion and work focus management because these substances control ADHD symptoms of inattention and hyperactivity and impulsivity.

    Advantages
    :

    Stimulant medications stand as the leading ADHD treatment option because they produce substantial symptom relief in 70-80% of patients (Faraone et al., 2021). Malcolm and Jessica would benefit from this treatment because these medications activate rapidly within 30 minutes per research by Biederman et al. (2019). The medication generates certain unwanted effects, such as troubles with sleep and reduced food intake and headaches that might affect regular activities (Banaschewski et al., 2017). Clinicians need to handle prescription decisions with manufactured drugs by evaluating legal ethical and social factors along with the potential for adult misuse and addiction (Faraone et al., 2021).

    Disadvantages
    :

    Side Effects
    : The common adverse effects of this treatment involve sleep disturbances and appetite reduction together with headaches and stomachaches, according to research by Banaschewski et al. (2017). Malcolm may face intense difficulties with appetite loss and sleep disturbances which would harm his school performance because of these side effects.

    Potential for Abuse
    : The addiction potential of stimulants and especially amphetamines poses a major issue when considering extended-term use (Faraone et al., 2021). Malcolm being a child faces less concern regarding stimulant misuse yet Jessica should receive extra attention since she has a substance abuse background and is an adult.

    Legal, Ethical, and Social Implications
    :

    Legal
    : Stimulant medications function as controlled substances since they possess the ability to create addictive behaviors among users. Medical authorities face regulatory obstacles while prescribing medication to children especially when using amphetamine-based drugs (Biederman et al., 2019).

    Ethical
    : When prescribing stimulant drugs to children or adults health providers need to weigh both symptom relief advantages against the possible adverse effects combined with substance misuse risks (Faraone et al., 2021).

    Social
    : The negative public attitude toward ADHD medications and particularly stimulants creates social judgments toward patients who take these medicines. Taking medication creates the potential for Jessica to experience colleagues’ negative opinions which might negatively impact her relationships at work.

    Con: Non-Stimulants

    Mechanism of Action
    : The non-stimulant psychiatric drugs atomoxetine and guanfacine operate according to distinct mechanisms compared to stimulants. Atomoxetine functions as a norepinephrine reuptake inhibitor that raises brain norepinephrine similar to stimulants at doses which prevent stimulant effects (Pringsheim et al., 2016). The medication serves to improve focus while reducing impulsivity while eliminating the danger of drug misuse. Guanfacine functions as a brain prefrontal cortex alpha-2 adrenergic agonist to improve attention and control impulses (Biederman et al., 2017).

    Advantages
    :

    Lower Abuse Potential
    : Non-stimulant medications lack any potential for abuse making them particularly beneficial for patients such as Jessica who possess substance abuse history (Pringsheim et al., 2016). Patients who are susceptible to addiction find non-stimulant medications appealing because they present no risk of abuse.

    Fewer Side Effects
    : Non-stimulants show superior tolerability because they generate lesser side effects than stimulants. The lower sleep impairment and appetite reduction rates that appear in non-stimulant drugs (Biederman et al., 2017) make these medications suitable for Malcolm who experiences these particular side effects.

    Disadvantages
    :

    Slower Onset
    : Non-stimulant medications require an extended period before patients can experience their maximum therapeutic advantages and typically need weeks of treatment to be effective according to Pringsheim et al. (2016). Malcolm faces potential challenges because he will need rapid symptom relief to control his academic conduct.

    Less Efficacy
    : Non-stimulants deliver effective results for numerous patients yet their therapeutic power remains lower than that of stimulants. Research demonstrates that non-stimulants achieve good results for between fifty and sixty percent of patients according to Pringsheim et al. (2016). Jessica might fail to achieve adequate symptom control through non-stimulants because her work and social difficulties need quicker and potent symptom management.

    Legal, Ethical, and Social Implications
    :

    Legal
    : Non-stimulant medications are less limited by restrictions from the law which allows doctors to provide them relatively easily to monitor adult patients specifically like Jessica according to Biederman et al. (2017).

    Ethical
    : The process of prescribing non-stimulants requires healthcare providers to account for the medication’s delayed onset which can lead patients to become dissatisfied. Patients need realistic expectation management with supportive care from healthcare providers during non-stimulant medication first months of usage (Pringsheim et al., 2016).

    Social
    : Some social groups believe ADHD treatment achieves legitimacy only when stimulant medications are used which causes them to view non-stimulant medications as less effective. The misconceptions about non-stimulant medications could affect the reception Jessica receives from her colleagues and social contacts regarding her treatment.

    Conclusion

    The therapeutic advantages and side effects of stimulant and non-stimulant medications produce distinct features when treating ADHD symptoms. Amphetamines and Methylphenidate demonstrate quick effects and strong performance but patients must consider the dangers of side effects with both potential misuse risks. Non-stimulants provide substance abuse safety for patients but their effects develop more slowly and might be less powerful than stimulants in treating ADHD symptoms. The best treatment for Malcolm could be stimulants because they deliver rapid symptom control yet the optimal choice for Jessica is a non-stimulant because of her work history and decreased chance of addiction.

    References

    Banaschewski, T., Buitelaar, J. K., & Roy, A. (2017). The role of stimulant medication in the treatment of ADHD: A systematic review. 
    European Child & Adolescent Psychiatry, 26
    (5), 521-536. 
    https://doi.org/10.1007/s00787-017-0952-6
    Links to an external site.

    Biederman, J., Mick, E., & Faraone, S. V. (2019). The effects of stimulant medications on attention deficit hyperactivity disorder in children and adults: A systematic review and meta-analysis. 
    American Journal of Psychiatry, 176
    (7), 541-549. 
    https://doi.org/10.1176/appi.ajp.2019.18070902
    Links to an external site.

    Faraone, S. V., Asherson, P., Biederman, J., & Mick, E. (2021). Attention-deficit hyperactivity disorder. 
    Lancet, 379
    (9830), 376-385. 
    https://doi.org/10.1016/S0140-6736(11)60750-9
    Links to an external site.

    Pringsheim, T., Gardner, D. M., & Addington, D. (2016). Non-stimulant treatment options for ADHD. 
    CNS Drugs, 30
    (5), 451-462. 
    https://doi.org/10.1007/s40263-016-0351-9
    Links to an external site.

    Neurocognitive Medications

    Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that is primary characterized by persistent and trans-situational patterns of age-inappropriate levels of inattention, hyperactivity, and impulsivity that interfere with normal development, personal functioning and well-being ( Goldin, 2023). Even though ADHD is prevalent in children, it can persist trough adolescent and adulthood. ADHD has been associated with reduced academic performance in children and adolescents and also can impede social and occupational achievement in the workplace. ADHD is a multifaceted neuro-disorder and it can be challenging to manage and reach optimized patients outcomes. Stimulants medications are commonly used to manage ADHD, not to cure them.

    The two classes of stimulants that I choose are: Amphetamine and Non-stimulant

    Amphetamine

    Mechanism of action

    Amphetamine is a releasing agent and reuptake inhibitor of dopamine and norepinephrine in the prefrontal cortex, which enhance the efficiency of information processing at pyramidal neurons, resulting in the improvement of symptoms in ADHD (Stahl, 2021). This medication class is the recommended first-line therapy in children because of their greater efficacy (AAP, 2019). Studies have shown hat approximately 80% of children with ADHD have fewer symptoms after finding the correct stimulant medication and dosage (AAP, 2019)

    Patient 1

    In this case we have a pediatric patient, 9 year old with ADHD/hyperactivity who cannot focus in class and is easily distracted.

    Advantages /Disadvantages of Amphetamines

    Amphetamines meds are available in tablets, capsules but also in liquid form for children. This is an advantage for children that are not able to swallow pills. They have to be started at a lower dosage and adjust weekly according to the patient’s response to the medication.

    Amphetamine versus Non stimulant

    Evidence has shown that for elementary school- aged students, stimulant medications such as Amphetamine is strong and sufficient for the management of ADHD copied to Non stimulant meds (AAP , 2019). Non-stimulants have more cardiac side effects and should be prescribed with more precautions

    Possible side effects of amphetamine

    The most common side effects of amphetamines are loss of appetite, insomnia, nervousness, social withdrawal and jitteriness in some cases (APA, 2019). There is also some growth concern associated with long term use of amphetamine so pediatric patient needs to be regular evaluated by their PCP. It also can cause tics in children and may prompt a discontinuation of the medication.

    Legal, ethical and social implications with Amphetamine prescription

    FDA legally approves amphetamines, for management of ADHD in children and this has to be explained to patient caregivers.

    For example for this pediatric patient, it is important to explain to patient that amphetamine is a controlled medication that the child may develop a dependency NURS-6630 Week 6: Discussion Patient Case Scenario Debate.

    Parents might be worried about the side effects of the medication and want to avoid given it o their child for another reason. Assessing the disposition of the parents towards the medication management is important. The American Academy of Podiatry (AAP,2019) recommends behavioral therapy along with ADHD medication. This child can also benefit from additional behavioral interventions in the classroom.

    Reassure parents that the primary will be working closely with them and adjust treatment as needed to provide the best possible outcome for the family and the child.

     

    Patient 2

    This patient is a 32-year-old patient with ADHD that is struggling in her workplace and here to discuss medication management.

    As explained by Stahl (2021), it is important to assess other comorbidities in the patients such as anxiety, substance abuse or mood disorders, because without addressing those, it is difficulty to get to an optimized treatment of ADHD in adults populations. Assuming that this patient does not have any of these comorbidities, Amphetamine is also a good choice in this case.

    Side effects are almost similar to the ones in children. Amphetamine can also cause dose-dependence and may be managed by either decreasing the dose or changing the time when medication is taken. Some adults may experience mood lability as an adverse side effect and it is recommended to switch to another stimulant or switching to non-stimulant medication (NIMH, 2024).

     

    Non-Stimulants

    Mechanism of action

    Non-stimulant such as selective norepinephrine reuptake inhibitor work by increasing norepinephrine levels in the brain.

    Non-stimulant class of medications such as Atomoxetine, clonidine and guafacine are also approved for the treatment of ADHD.

    Advantage /disadvantage of non-stimulants

    Non-stimulant medications are the next best treatment option for ADHD but not as effective as stimulants. It is recommended to try a non-stimulant meds if patient having intolerable side effects ( Kolar et al., 2008). For adult’s patient such as Patient 2, if she is not able to tolerate Amphetamine, we can use non-stimulant options such as atomoxetine.

    An important advantage of non-stimulant such as Atomoxetine, is that, it does not have an abuse potential. This is very important consideration when it comes to adults who are at risk for substance abuse. Other advantage is that Atomoxetine is once a day, less rebound and has mild anti-anxiety effect (CADDRA, 2006).

    Side effects of non-stimulant meds

    When taking Atomoxetine for example, patient may experience some side effects such as headache, increase BP, increased HR, weight loss mild, sexual dysfunction, upset stomach and poor appetite. Regular follow up sis advised.

    Legal, ethical consideration with non-stimulant prescriptions

    Before prescribing the non-stimulant medications, we should explain medication action, informed consent with the patient to be able to make her own decision. Side effects should be discussed with patient and caregivers. Assure the patient that confidentiality will be maintained.

    Conclusion

    Amphetamine and non-stimulants are both class of medications used in the management of ADHD. It can be used together depend on the symptoms we are treating.

    For this two patients discussed in this case, Amphetamine should be considered as a first line of treatment and adjust as tolerated.

     

    References

    American Academy of Pediatrics. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. https://doi.org/10.1542/peds.2019-2528

    Canadian ADHD Practice Guidelines (CADDRA). ( 2006). Appendices Medications for ADHD.

    Kolar, D. , Keller, A., Golfinopoulos, M., Cumyn, L., Hechtman, L. ( 2008). Treatment of adults with attention-deficit /hyperactivity disorder. doi: 10.2147/ndt.s6985. PMID: 18728745; PMCID: PMC251838

    Goldin, S.S. (2023). Fast Facts for psychopharmacology for nurse practitioners. Springer Publishing.

    Stahl, S. M. (2021). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (5
    th
     ed.). Cambridge University Press.

    National Institute of Mental Health. (2024). Attention-Deficit/Hyperactivity Disorder. 
    https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd
    Links to an external site.

     

     

     

    Expand discussion thread from Akuvi Akpedze Didi Agbo Atchon

    2 Replies, 2 Unread

    2 Replies, 2 Unread

    Reply to post from Akuvi Akpedze Didi Agbo Atchon
    Reply

    Mark as Unread
    Mark as Unread

    DD

    Doris Dickson

    Apr 1, 2025 1:42pm

    Reply from Doris Dickson

    Week 6: 
    Discussion

    Patient 2:

    Jessica is a 32-year-old female that was recently diagnosed with ADHD. She was referred to your office by the psychologist that completed the ADHD assessment. Jessica has always struggled in school and jobs. She is often “written up” at her job for not completing tasks that are assigned to her. She becomes easily distracted by her other co-workers. She finds herself spending a lot of time conversing with colleagues. Her colleagues are frequently annoyed with her for constantly talking to them and interrupting their work and tasks. Jessica is here to discuss medication options to treat ADHD.

     

    Proposed Mechanism Action of the Medication

    Amphetamines 
    like Adderall increase the amounts of dopamine and norepinephrine in the human brain. Stimulants hypothetically increase the availability of both dopamine and norepinephrine in prefrontal cortex, which enhances the efficiency of information processing at pyramidal neurons, resulting in the improvement of symptoms in attention-deficit/hyperactivity disorder (Stahl, S. 2010). In a nutshell, neurotransmitters are said to be linked with attention, focus, and impulse control, that are naturally lacking in individuals with ADHD. And enhancing these neurotransmitters, amphetamines can possibly help in improving Jessica’s attention span and decrease her hyperactive and impulsive behaviors.

    Advantages:

    Amphetamines are highly effective in decreasing ADHD symptoms in various patients.

    • The short-acting and long-acting drug form, offers flexibility in managing the symptoms.

    • They are widely available and frequently prescribed with well-known dosing guidelines.

    Disadvantages:

    Its side effect has been linked with increased heart rate, insomnia, anxiety, and potential for dependence, tolerance or abuse.

    • It is not ideal or recommendable for patients with history of substance abuse, cardiovascular disease, or severe anxiety.

    Methylphenidate
    , such as Ritalin or Concerta, work by obstructing the reuptake of dopamine and norepinephrine, like amphetamines but through a different mechanism. As a result of the inhibition, it results to increased levels of the neurotransmitters in the synaptic cleft, enhancing attention and reducing impulsivity and hyperactivity.

    Advantages:

    Effective in managing ADHD symptoms.

    • Available in short-acting, intermediate-acting, and extended-release which enhances the flexibility of managing the symptoms.

    • It has a lower potential for abuse compared to Amphetamines.

    Disadvantages:

    Have side effects like, insomnia, loss of appetite, weight loss, increased heart rate, and blood pressure.

    • Caution when used for patients with a history of cardiac disease and anxiety disorders.

    Comparative Analysis

    Amphetamines Over Methylphenidate:

    • Greater Efficacy

    *Longer Duration leading in reducing the need for multiple doses throughout the day.

    Methylphenidate Over Amphetamines:

    • Lower Abuse Potential compared to amphetamines.

    • Lower or fewer side effect record with methylphenidate.

    Both Possible side effects or considerations needed to be evaluated

    The two classes of medications likely to increase heart rate or blood pressure. It is essential that clinicians monitor cardiovascular health patients.

    The two classes of medications can worsen anxiety or mood swings. Thus, patients with co-existing mental health disorders should be closely monitored.

    The Long-term use of the two medications, both in children or adolescent are likely to affect the rate of developments.

    Legal, Ethical, and Social Implications:

    Legal

    • Amphetamines, a Schedule II controlled substances, emanates a firm guideline about prescribing and dispensing. The end result can lead to possible legal penalties for misuse or alteration.

    • Methylphenidate, a Schedule II controlled substance which has slightly lower tendency of an abuse potential, is still subject to strict regulatory control.

    Ethical

    • Prescribing amphetamines must be done ethically, with cautious deliberation of medical history and potential for substance abuse by the patient. Informed consent/permission is vital.

    • With Methylphenidate, similar importance must be adhered to by ensuring that patients understand the risks, benefits, and how to properly use the medication.

    Social

    • With Amphetamines, patients are likely to face the stigma of been judged or misunderstood amongst their peers or colleagues.

    • With Methylphenidate, although stigmatized, it’s been perceived as a safer option.

    In summary, stimulants are generally the first-line treatment for ADHD, but non-stimulants can be a valued substitute or adjunct therapy for patients who cannot tolerate or respond well to stimulants. The decision for clinician to which medication to prescribed must be individualized, by taking into account the patient specific symptoms, medical history, and personal preferences, along having a detailed lay man term discussion of the drug potential risks and benefits. This should be applied in the case of Jessica. In her case, both amphetamines and methylphenidate are likely to offer feasible choice for treating Jessica’s ADHD case, with each exhibiting their own set of benefits and downsides.

    .

     

     

     

     

    References

    Stephen M. Stahl (2010). Mechanism of Action of Stimulants in Attention-Deficit/Hyperactivity Disorder. The Journal Clinical Psychiatry 2010;71(1):12-13. 
    https://www.psychiatrist.com/jcp/mechanism-action-stimulants-attention-deficit-hyperactivity/
    Links to an external site.

    Biederman, J., & Faraone, S. V. (2005). Attention-deficit hyperactivity disorder. Lancet, 366(9481), 237-248.

    Swanson, J. M., Wigal, S. B., & Volkow, N. D. (2011). Long-term outcomes of stimulant medication in ADHD: The Multimodal Treatment Study of Children with ADHD (MTA) at 8 years. Journal of the American Academy of Child & Adolescent Psychiatry, 50(11), 1125-1136.

     

     

     

    Reply to post from Doris Dickson
    Reply

    Mark as Unread
    Mark as Unread

    Beatrice Fertil

    Apr 1, 2025 12:20pm
    | Last reply Apr 2, 2025 11:05am

    Reply from Beatrice Fertil

    Beatrice’s main post with references

    Patient Case Scenario Debate

    Attention-Deficit/Hyperactivity Disorder (ADHD) is not an age-specific disease and thus affects both young and old populations. Although there are diverse pharmacotherapies for managing this condition, there is always debate on which drug is the best. The essay argues for the use of methylphenidate medications over amphetamines for patients with ADHD.

    Why Methylphenidate is the Preferred Treatment

    The mechanism of methylphenidate involves blocking the reuptake of dopamine and norepinephrine while enhancing cognitive function and improving impulse control (Cunill et al., 2021). Storebø et al. (2023) state that the drug is effective for ADHD management across all ages, thus ideal for both 9-year-old Malcolm and 32-year-old Jessica.

    Advantages of Methylphenidate (MPH)

    The potential for Methylphenidate to induce drug-induced psychosis is reduced across adolescent and adult patients, hence providing a safer option for ADHD treatment (Hamard et al., 2024). Patients gain enhanced management of their treatment plan when using extended-release and short-acting methylphenidate formulations because this treatment approach helps decrease adverse impacts such as insomnia and appetite reduction. The low-to-no risk of dependence and misuse makes MPH appropriate for patients requiring extended treatment of ADHD symptoms. The availability of short-acting and extended-release forms of the drug matches the needs of individuals who need sustained control of their symptoms.

    Why Amphetamines Are Less Suitable

    The dopamine-releasing properties of amphetamines enhance their potency while elevating the likelihood of dependence (Hamard et al., 2024). Amphetamines will more frequently cause psychotic symptoms, particularly among young adults and adolescents, hence proving less appropriate for Jessica’s treatment. Long-term health risks arise from cardiovascular side effects produced by amphetamines.

    Conclusion

    Research shows Methylphenidate represents a safe and effective solution for treating ADHD while presenting a reduced potential for psychotic episodes and addiction. Methylphenidate stands as the most suitable medication option to treat ADHD patients across both pediatric and adult age groups because of its safety features and adaptability.

     

     

    Reference

    Cunill, R., Castells, X., & Tobias, A. (2021). Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review. 
    Psychopharmacology
    , 238(10), 2667–2691. 
    https://doi.org/10.1007/s00213-021-05946-0
    Links to an external site.

    Hamard, J., Rousseau, V., Durrieu, G., Garcia, P., Yrondi, A., Sommet, A., … & Montastruc, F. (2024). Psychosis with use of amphetamine drugs, methylphenidate and atomoxetine in adolescent and adults. 
    BMJ Ment Health
    , 
    27
    (1). 
    https://doi.org/10.1136/bmjment-2023-300876
    Links to an external site.

    Storebø, O. J., Storm, M. R. O., Ribeiro, J. P., Skoog, M., Groth, C., Callesen, H. E., … & Gluud, C. (2023). Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). 
    Cochrane Database of Systematic Reviews
    , (3). 
    https://doi.org/10.1002/14651858.CD009885.pub3
    Links to an external site.

    Expand discussion thread from Beatrice Fertil

    2 Replies, 2 Unread

    2 Replies, 2 Unread

    Reply to post from Beatrice Fertil
    Reply

    Mark as Unread
    Mark as Unread

    Beatrice Fertil

    Apr 1, 2025 12:03pm

    Reply from Beatrice Fertil

                                                 Beatrice’s main post:

    Patient Case Scenario Debate

    Attention-Deficit/Hyperactivity Disorder (ADHD) is not an age-specific disease and thus affects both young and old populations. Although there are diverse pharmacotherapies for managing this condition, there is always debate on which drug is the best. The essay argues for the use of methylphenidate medications over amphetamines for patients with ADHD.

    Why Methylphenidate is the Preferred Treatment

    The mechanism of methylphenidate involves blocking the reuptake of dopamine and norepinephrine while enhancing cognitive function and improving impulse control (Cunill et al., 2021). Storebø et al. (2023) state that the drug is effective for ADHD management across all ages, thus ideal for both 9-year-old Malcolm and 32-year-old Jessica.

    Advantages of Methylphenidate (MPH)

    The potential for Methylphenidate to induce drug-induced psychosis is reduced across adolescent and adult patients, hence providing a safer option for ADHD treatment (Hamard et al., 2024). Patients gain enhanced management of their treatment plan when using extended-release and short-acting methylphenidate formulations because this treatment approach helps decrease adverse impacts such as insomnia and appetite reduction. The low-to-no risk of dependence and misuse makes MPH appropriate for patients requiring extended treatment of ADHD symptoms. The availability of short-acting and extended-release forms of the drug matches the needs of individuals who need sustained control of their symptoms.

    Why Amphetamines Are Less Suitable

    The dopamine-releasing properties of amphetamines enhance their potency while elevating the likelihood of dependence (Hamard et al., 2024). Amphetamines will more frequently cause psychotic symptoms, particularly among young adults and adolescents, hence proving less appropriate for Jessica’s treatment. Long-term health risks arise from cardiovascular side effects produced by amphetamines.

    Conclusion

    Research shows Methylphenidate represents a safe and effective solution for treating ADHD while presenting a reduced potential for psychotic episodes and addiction. Methylphenidate stands as the most suitable medication option to treat ADHD patients across both pediatric and adult age groups because of its safety features and adaptability.

     

     

    Reply to post from Beatrice Fertil
    Reply

    Mark as Unread
    Mark as Unread

    UH

    Uzoamaka Promise Harrison

    Apr 1, 2025 9:54am
    | Last reply Apr 4, 2025 8:10pm

    Reply from Uzoamaka Promise Harrison

    Main Post

    Patient 1: Malcolm (9-year-old with ADHD, Combined Presentation)

    One common medication that is taken by children with ADHD is amphetamine because these chemicals have an impact on the chemicals dopamine and norepinephrine which control concentration and impulse control. They have a quick onset, making them effective for immediate symptom relief (Arkell et al., 2022). However, it has some side effects including insomnia, loss of appetite, and the possibility of being abused. Since they are classified under the controlled substances, they should always be closely monitored. Also, there are ethical issues of dependence, and the latter is unfavorable perception of stimulant consumption by children.

    Non-stimulant occupies the same receptors as stimulants but do not engross dopamine making it safer for children who suffer from anxiety. They have relatively fewer side effects involving appetite and sleep but may take several weeks to produce the maximum effect which may further affect their academic enhancement (Radonjić et al., 2023). Even if they neglect stimulant-related risks, they do not necessarily do so with hyperactivity. They are easier to prescribe in a legal way but their side effect is that their effectiveness is delayed which may hamper school performance. From social point of view, parents may have a preference for them over stimulants.

    Patient 2: Jessica (32-year-old female with ADHD)

    Regarding the choice of medication for Jessica, I would prescribe amphetamines because they increase dopamine and norepinephrine quickly and affect the executive functions. Compared to other agents, they are well researched in adults and could enhance her work productivity greatly. However, the medication has certain side effects like anxiety, insomnia, and heart issues (Steinbuchel  Greenhill 2020). Since amphetamines belong to the controlled substances the prescription requires monitoring, and there is an ethical issue of overprescribing. Another reason may be socially, there are prejudices when it comes to taking medications for adult ADHD.

    Non- stimulants may be safer either in case Jessica suffers from anxiety or has a history of any substance usage. These medications help in raising the levels of norepinephrine and are useful in addressing the issues of attention and impulsivity without the likelihood of the patient becoming addicted (Radonjić et al., 2023). However, they may take longer to occur and this is likely to affect her in terms of the job performance in the initial phase. They are also easier to prescribe from the legal point of view, and the impact on the society is not as negative as that of stimulants. In ethical terms, this slow effectiveness has to be considered against her desire for relief from the symptoms of her condition.

    References

    Arkell, T. R., Bradshaw, K., Downey, L. A., & Hayley, A. C. (2022). Acute effects of amphetamine and related psychostimulants on impulsivity: A systematic review of clinical trials. 
    Addiction Biology
    , 
    27
    (2). 
    https://doi.org/10.1111/adb.13128
    Links to an external site.

    Radonjić, N. V., Bellato, A., Khoury, N. M., Cortese, S., & Faraone, S. V. (2023). Nonstimulant medications for attention-deficit/Hyperactivity disorder (ADHD) in adults: Systematic review and meta-analysis. 
    CNS Drugs
    , 
    37
    (5), 381-397. 
    https://doi.org/10.1007/s40263-023-01005-8
    Links to an external site.

    Steinbuchel, P., & Greenhill, L. (2020). Stimulants: Definition, pharmacology, indications, side effects, and treatment strategies. 
    NeuroPsychopharmacotherapy
    , 1-29. 
    https://doi.org/10.1007/978-3-319-56015-1_324-1
    Links to an external site.

     

    Expand discussion thread from Uzoamaka Promise Harrison

    3 Replies, 3 Unread

    3 Replies, 3 Unread

    Reply to post from Uzoamaka Promise Harrison
    Reply

    Mark as Unread
    Mark as Unread

    YL

    Yamila Casas Lay

    Apr 1, 2025 5:06am
    | Last reply Apr 2, 2025 5:42pm

    Reply from Yamila Casas Lay

    Selected Medication Classes: Amphetamine and Methylphenidate

    Both cases involve patients diagnosed with attention-deficiency/hyperactivity disorder (ADHD). Malcolm in patient 1’s case study is a child in grade 4, while in patient 2, the patient is Jessica, an adult suffering from the problem. According to Veronica (2021), ADHD is a neurodevelopmental disorder whose traits include persistent patterns of hyperactivity, inattention, and impulsivity. It interferes with the daily development and functioning of a person. The authors wrote that the etiology of the condition is diverse, including the presence of variants of some genes and environmental factors. In both case studies, the reported symptoms are linked with the condition, for example, fidgeting, hyperactivity, blurting out answers, hitting other children, a lack of focus, forgetfulness, distraction, a struggle in jobs and school, not completing assigned tasks, and annoying colleagues.

    Both methylphenidate and amphetamine are stimulants and increase the dopamine and norepinephrine levels in the brain. However, the mechanisms may be different. Henry et al. (2022) wrote that amphetamine primarily acts as a releasing agent and reuptake inhibitor. On the other hand, methylphenidate acts as a reuptake inhibitor. The increase in the dopamine and norepinephrine levels in the brain is critical and impacts the executive and attentional functions, hence managing the symptoms of ADHD. NURS-6630 Week 6: Discussion Patient Case Scenario Debate

    There are advantages of using methylphenidate and amphetamine in the management of ADHD. According to Dutta et al. (2022), the aspect of increasing the central dopamine and norepinephrine activity by the two drugs, impacting the executive and attentional function of a person, is an advantage. The two are the first-line medications for the disease. However, there are associated side effects, including increased blood pressure and heart rate, potential for abuse, psychosis, insomnia, mood swings, and decreased appetite.

    Compared to other medications for ADHD, for example, alpha-adrenergic Agonist, methylphenidate and amphetamine have a higher efficiency in the management of ADHD, more so in the reduction of associated symptoms. However, in terms of side effects and potential abuse, Alpha Adrenergic Agonist as a non-stimulant is better compared to the two drugs.

    Both methylphenidate and amphetamine may be effective in increasing the dopamine and norepinephrine levels in the brain and impacting the executive and attentional functions in a patient. However, they have side effects and there are considerations to evaluate. For example, they have the potential for abuse, can induce psychosis, bring about irritability, headache, and stomach pain, produce sleep disturbances, increase blood pressure and heart rate, decrease appetite, and cause anxiety.

    The legal consideration in the use of methylphenidate and amphetamine is the need to have prescriptions done by a qualified and registered healthcare provider. The ethical consideration is the need to uphold the autonomy or independence of the patient and seek informed consent. The social consideration is the observation of some social behaviors.

    References

    Dutta, C. N., Ombao, H., & Douglas, P. K. (2022). Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan. 
    Frontiers in Human Neuroscience
    , 
    16
    , 938501. 
    https://doi.org/10.3389/fnhum.2022.938501
    Links to an external site.

    Henry, T. R., Fogleman, N. D., Nugiel, T., & Cohen, J. R. (2022). Effect of methylphenidate on functional controllability: A preliminary study in medication-naïve children with ADHD. 
    Translational Psychiatry
    , 
    12
    (1), 1-9. 
    https://doi.org/10.1038/s41398-022-02283-4
    Links to an external site.

    Verónica, W. (2021). ADHD: Reviewing the causes and evaluating solutions. 
    Journal of Personalized Medicine
    , 
    11
    (3), 166. 
    https://doi.org/10.3390/jpm11030166
    Links to an external site.

    Expand discussion thread from Yamila Casas Lay

    2 Replies, 2 Unread

    2 Replies, 2 Unread

    Reply to post from Yamila Casas Lay
    Reply

    Mark as Unread
    Mark as Unread

    AF

    Arnaud Momo Fopa

    Apr 1, 2025 1:10am

    Reply from Arnaud Momo Fopa

    What is the proposed mechanism of action of the medication(s)? Why might this be appropriate for the patients?

    Amphetamines increase the availability of dopamine and norepinephrine in the brain by promoting their release and blocking their reuptake. This improves attention, focus, and impulse control (Paul, 2021). For Malcolm, a 9-year-old with ADHD combined presentation, amphetamines are appropriate because they can quickly reduce hyperactivity and impulsivity, allowing for better classroom behavior and task completion. For Jessica, a 32-year-old with workplace challenges due to distractibility and disorganization, amphetamines may enhance her ability to concentrate and follow through with tasks.

    Alpha-adrenergic agonists, such as clonidine and guanfacine, act on alpha-2 adrenergic receptors in the brain to reduce sympathetic nervous system activity. This results in a calming effect, which can help with symptoms like impulsivity, aggression, and hyperactivity. These medications may be appropriate for Malcolm, especially if he experiences difficulty with emotional regulation or has trouble winding down at night. However, for Jessica, whose primary symptoms involve inattention and executive dysfunction, alpha agonists may not be as effective as stimulant medications.

    What are the advantages or disadvantages to your class of medication (options for different administration, length of duration, etc.)?

    Amphetamines are available in multiple formulations, including short-acting, intermediate, and extended-release, allowing for individualized treatment plans (Fu & Wang, 2023). Extended-release options offer the convenience of once-daily dosing, which is particularly helpful for school-aged children like Malcolm. These medications also provide a rapid onset of action and significant symptom improvement. However, disadvantages include the risk of insomnia, appetite suppression, and mood changes. They require careful titration and monitoring for potential misuse or dependence, especially in adults.  Also, Alpha adrenergic agonists are non-stimulant medications with lower abuse potential. They are often used as monotherapy or adjuncts to stimulants, especially in children with comorbid conditions like tics or sleep disturbances. Extended-release formulations allow for smoother dosing throughout the day. However, these medications often take several weeks to show full effectiveness and may cause side effects such as fatigue, low blood pressure, or dizziness. They are less effective in addressing core inattentive symptoms of ADHD.

    What are the advantages or disadvantages to the other medication options?

    Compared to alpha adrenergic agonists, amphetamines provide stronger and faster symptom relief, particularly for inattention and hyperactivity. They are generally considered first-line treatment for ADHD due to their proven efficacy (Fu & Wang, 2023). However, they also come with higher risks of side effects and misuse, particularly in adolescent and adult populations. On the other hand, alpha agonists may be safer for long-term use in children or individuals with a history of substance abuse. While they may help reduce behavioral issues like impulsivity and aggression, they do not significantly improve attention span or executive function in most cases. Their slower onset and sedating effects can also impact functioning, particularly for adults like Jessica.

    What possible side effects or considerations need to be evaluated?

    With amphetamines, common side effects include decreased appetite, sleep disturbances, headaches, mood swings, and potential increases in blood pressure or heart rate (Fu & Wang, 2023). In children, there may also be concerns about growth suppression with long-term use. Regular monitoring and dosage adjustments are essential. In adults like Jessica, cardiovascular health must be considered, especially if underlying conditions exist. For alpha adrenergic agonists, side effects such as drowsiness, dizziness, dry mouth, and hypotension should be closely monitored (Root-Bernstein, 2022). These medications can be particularly sedating, which may affect daytime functioning, especially in adults. Gradual tapering is also required when discontinuing to avoid rebound hypertension.

    Provide one example for each consideration—legal, ethical, and social implications—for prescribing the medication category.

    Legal consideration
    : Amphetamines are classified as Schedule II controlled substances, requiring strict documentation and follow-up (Guan et al., 2023). Alpha-2 Prescribers must ensure proper storage, prescribing limits, and regular evaluations, especially when treating adults like Jessica.

    Ethical consideration
    : There is an ethical obligation to avoid over-prescription or misuse of stimulants. In pediatric cases like Malcolm’s, prescribers must ensure that medication is part of a comprehensive treatment plan including behavioral support, rather than used as a quick fix for disruptive behavior.

    Social consideration
    : Both Malcolm and Jessica may face stigma around ADHD and the use of stimulants. Malcolm may be labeled as a “troublemaker” or seen as overly medicated, while Jessica might feel judged or misunderstood at work due to her diagnosis and treatment. Educating families, patients, and communities about ADHD and treatment options can help reduce stigma and promote understanding.

    References

    Fu, Y. P., & Wang, Y. (2023). Amphetamines abuse and depression: Focus on TRPC channels. 
    Experimental Neurology
    , 
    364
    , 114391.

    Guan, M., Fanelli, D., Verbeek, T., Warfield Jr, D. J., & Liu, H. (2023). Alpha-2 Adrenergic Agonists. In 
    First Aid Perioperative Ultrasound: Acute Pain Manual for Surgical Procedures
     (pp. 169-194). Cham: Springer International Publishing.

    Paul, A. (2021). Adrenergic agonists. 
    Introduction to Basics of Pharmacology and Toxicology: Volume 2: Essentials of Systemic Pharmacology: From Principles to Practice
    , 41-53.

    Root-Bernstein, R. (2022). Adrenergic agonists and antagonists enhance opioid receptor activity. In 
    The Neurobiology, Physiology, and Psychology of Pain
     (pp. 79-89). Academic Press.

    Reply to post from Arnaud Momo Fopa
    Reply

    Mark as Unread
    Mark as Unread

    NA

    Nancy Ansah

    Mar 31, 2025 3:30pm

    Reply from Nancy Ansah

    For this discussion, I have selected these two classes of medications used to treat ADHD: Methylphenidate and Non-Stimulant medications:

    Methylphenidate

    Mechanism of Action

    Methylphenidate is a central nervous system stimulant whose primary action is to elevate brain levels of dopamine and norepinephrine. It inhibits their reuptake in the brain, thereby their availability in the synaptic cleft increases (Verghese & Abdijadid, 2023). This process leads to increased concentration, reduces hyperactivity, and facilitates impulse control. For Malcolm (9 years old), methylphenidate would be appropriate because it affects both the inattention and hyperactivity symptoms of ADHD. In Jessica’s situation, methylphenidate can help improve her distractibility and impulsivity issues at the workplace.

    Advantages

    Rapid onset of action: Methylphenidate is fast-acting (Verghese & Abdijadid, 2023), which is best in school or work environments where faster improvement is needed.

    Multiple formulations: It comes in immediate-release, extended-release, and long-acting forms, providing convenience with dosing schedules and duration of action.

    Well-established effectiveness: It is among the most researched drugs for ADHD and has a well-established history of effectiveness.

    Disadvantages:

    Side effects: Insomnia, loss of appetite, increased heart rate, and risk of heightened anxiety or irritability are common side effects.

    Short acting (for immediate-release formulation): The immediate-release formulation (PubChem, 2019), requires multiple doses per day, which can be difficult for Malcolm if he has to manage multiple doses while at school.

    Abuse potential: As a stimulant, methylphenidate has an abuse potential, especially in teenagers or young adults.

    Side Effects/Considerations:

    Legal: Methylphenidate is a controlled drug due to its potential for abuse. The prescribing clinician must consider this when treating individuals who may have a history of drug abuse.

    Ethical: Ethical concerns include long-term administration of the stimulant drug in children like Malcolm, where there may be concern regarding their developing habit or drug abuse in later life.

    Social: Stigmatisation is likely, particularly in children. Children on stimulant drugs can have problems with acceptance by educators or peers, and some may face adverse social consequences.

    Non-Stimulant Medications (e.g. Atomoxetine)

    Mechanism of Action

    Atomoxetine, a non-stimulant, is one such drug that selectively inhibits the reuptake of norepinephrine (Fedder et al., 2023). It has minimal effect on dopamine levels but still increases the level of norepinephrine in the synapse, which can improve attention and concentration in ADHD patients (
    Drugs & Medications
    , n.d.). Atomoxetine may be a suitable option for Jessica since it lacks the abuse liability of stimulants.

    Advantages:

    No potential for abuse: Atomoxetine is not a controlled substance, so it is a safer option for substance abuse patients or those at risk, such as Jessica.

    Long-acting: Atomoxetine is a once-a-day medication, which is easier to manage for adults and older children who have difficulty with more than one dose (Fedder et al., 2023).

    Fewer side effects: It has a lower incidence of sleep disturbance or appetite suppression compared to stimulants, making it preferable to Malcolm if these are a concern.

    Disadvantages:

    Slower onset of action: Atomoxetine may take weeks to achieve its full effect, which makes it less ideal in the event that instantaneous relief of symptoms is required.

    Possible side effects: Possible side effects include stomach discomfort, tiredness, and mood changes, which restricts its use in certain patients.

    Side Effects/Considerations

    Legal: Atomoxetine is not controlled, but the prescriber still needs to ensure proper documentation, particularly in the case of adults like Jessica, who may need to be monitored for abuse of other medications.

    Ethical: There may be ethical concerns in prescribing a medication like atomoxetine to children when it takes longer to exert its effects, thereby causing frustration among parents and teachers.

    Social: Social considerations include the threat that individuals on atomoxetine, especially children, can be ostracized or stigmatized compared to their peers on more rapidly acting stimulant medications.

    References

    Drugs & Medications
    . (n.d.). Www.webmd.com. https://www.webmd.com/drugs/2/drug-64629/strattera-oral/details

    Fedder, D., Patel, H., & Saadabadi, A. (2023, March 27). 
    Atomoxetine
    . PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK493234/

    PubChem. (2019). 
    Methylphenidate
    . Nih.gov; PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/4158

    Verghese, C., & Abdijadid, S. (2023, January 2). 
    Methylphenidate
    . Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482451/ NURS-6630 Week 6: Discussion Patient Case Scenario Debate

  • A provider performs an eye examination during a health maintenance visit and notes a difference of 0.5 mm in size between the patient’s pupils. What does this finding indicate?

    A provider performs an eye examination during a health maintenance visit and notes a difference of 0.5 mm in size between the patient’s pupils. What does this finding indicate?

    Group of answer choices

     

    A relative afferent pupillary defect

     

    Indication of a difference in intraocular pressure

     

    Likely underlying neurological abnormality

     

    Probable benign, physiologic anisocoria

  • NURS-6630 Week 5: Assignment De-Prescribing

    NURS-6630 Week 5: Assignment De-Prescribing

    Prescribing and Deprescribing in Diverse Populations

    Benzodiazepines and opioids are widely prescribed for managing anxiety and chronic pain, but their long-term use presents significant concerns, including dependence, withdrawal symptoms, cognitive impairment, and overdose risks. A structured method should be used for de-prescribing these medications because it helps minimize withdrawal symptoms without compromising symptom control (Montes-Castrejon et al., 2024).  This paper examines patient-specific de-prescribing strategies, with a focus on individualized tapering protocols, patient education, and alternative treatments to enhance safety and efficacy.

    Patient 1: Improving Pain and Anxiety Through Tapering in Opioid Therapy

    The combination treatment of opioids with benzodiazepines produces heightened risks for sedation and respiratory depression, as well as cognitive decline and overdose risks. Clonazepam, a long-acting benzodiazepine, is commonly prescribed for panic disorders but has a high potential for dependence and withdrawal symptoms (Fung et al., 2024). The patient expressed concern about withdrawal side effects but agreed to stop taking clonazepam while continuing opioid treatment. A successful transition requires a systematic reduction plan, patient education, and safer pharmacologic and non-pharmacologic treatment options.

    The simultaneous use of opioids and benzodiazepines causes intensified sedation effects along with deepened respiratory depression, which increases the likelihood of deadly overdoses. Research shows that long-term benzodiazepine use induces cognitive decline, increases dependence on the drug, and creates serious withdrawal symptoms when patients stop (Finlayson et al., 2022). Periodic reductions in dosage must be part of every risk-mitigation plan. A tapering schedule of clonazepam 0.25 mg every 1-2 weeks will be implemented to help the body adapt while avoiding dangerous withdrawal symptoms. Follow-up evaluations will assess the patient’s treatment response, address concerns, and adapt the tapering protocol to ensure safety and optimal outcomes.

    For people with panic disorder, safer therapeutic options should be explored. Sertraline and other SSRIs work well to treat anxiety and panic episodes without the side effects of benzodiazepines (Archer et al., 2024). Buspirone offers further anxiolytic advantages without causing drowsiness or dependence. To help control symptoms over the long term, non-pharmacologic methods such as cognitive behavioral therapy (CBT) and relaxation techniques should be promoted.

    GET HUMAN-WRITTEN PAPER HERE

    From a legal and ethical standpoint, healthcare providers must adhere to evidence-based guidelines and utilize prescription monitoring programs to prevent misuse and addiction. The patient should actively participate in shared decision-making, ensuring they have informed consent regarding any medication changes and alternative treatments. Edinoff et al. (2021) state that addressing social barriers, such as the stigma associated with mental health care and access to alternative therapies, is also crucial for a comprehensive, patient-centered approach.

    Medication Order

    Medication Name
    : Sertraline

    Dose
    : 25 mg

    Administration Route
    : Oral

    Dosage Timing
    : One dose every morning

    Total Supply
    : 30 tablets

    Number of Refills
    : Three

    Instructions
    : If the medication is well tolerated, adjust the dose to 50 mg after two weeks. Schedule a follow-up in 2-4 weeks to evaluate progress.

    Medication
    : Clonazepam

    Dose
    : 0.75 mg

    Route
    : Oral

    Dosage Schedule
    : Twice daily while tapering

    Total Dispensed
    : 30 tablets

    Refills Authorized
    : None

    Instructions
    : Gradually decrease by 0.25 mg every 1-2 weeks. Monitor closely for withdrawal symptoms.

    Patient 2: Benzodiazepine Tapering for Panic Disorder

    The patient has been taking alprazolam for panic attacks, which are currently in remission. However, past efforts to stop the medication resulted in withdrawal symptoms, making the tapering process difficult. Withdrawal effects can range from mild issues like anxiety and insomnia to more serious complications such as seizures (Rosenthal & Burchum, 2021). Risk mitigation requires an organized tapering routine to transition gradually, minimizing potential threats. A prescription change toward the longer-acting benzodiazepine diazepam creates a smoother withdrawal process with enhanced symptom management. Patient education about withdrawal symptoms helps lower anxiety and enables better adherence to the scheduled tapering plan. The typical symptoms of withdrawal often manifest through restlessness, irritability, muscle tension, insomnia, and mild headaches NURS-6630 Week 5: Assignment De-Prescribing. Combining sustained guidance and continuing support leads to successful tapers that reduce patient discomfort.

    Patients need emergency medical assistance if they develop hallucinations, seizures, or cardiovascular distress during benzodiazepine withdrawal (Archer et al., 2024). Follow-up care includes instructions for the patient to stay hydrated, learn relaxation techniques, and establish a normal sleep schedule to manage withdrawal symptoms. Regular check-ups enable clinicians to assess progress and adjust medication dosage schedules accordingly.

    Alprazolam has a limited half-life; hence, switching to diazepam, a longer-acting benzodiazepine, is recommended. There are 10 milligrams of diazepam for every milligram of alprazolam. The patient will now take 1 mg of alprazolam BID twice daily, but diazepam (5 mg in the morning and 5 mg at night) will now be administered. To lessen withdrawal symptoms, the amount of diazepam will be tapered down by 1 mg every 1-2 weeks, depending on tolerance.

    To ensure long-term anxiety management, an SSRI such as sertraline should be introduced once tapering is underway. Cognitive behavioral therapy (CBT) is also highly effective in preventing panic attacks and should be encouraged as part of the treatment plan (Brandt et al., 2024). If additional support is needed, hydroxyzine may be used as an as-needed (PRN) medication for acute anxiety episodes.

    Medication Order

    Medication
    : Diazepam

    Dose
    : 5 mg

    Administration Route
    : Oral

    Dosage Schedule
    : Twice daily, in the morning and at bedtime

    Total Dispensed
    : 30 tablets

    Refills Authorized
    : None

    Special Instructions
    : Reduce by 1 mg every 1-2 weeks. Monitor for withdrawal symptoms. Follow up every two weeks.

    Patient 3: Safe Discontinuation and Alternative Anxiety Management in Pregnancy

    Lorazepam crosses the placenta and can accumulate in fetal tissues, increasing the risk of congenital disabilities, neonatal withdrawal, low birth weight, and respiratory issues (Meng et al., 2023). Exposure to lorazepam during the first trimester may increase the risk of cleft palate formation. However, later pregnancy use can result in neonatal withdrawal syndrome, which produces symptoms including excessive crying, feeding complications, and muscle tone abnormalities. Lorazepam passed to a nursing infant through breast milk leads to infant sedation and feeding difficulties. The potential pregnancy and breastfeeding risks of this medication exceed its therapeutic value, so discontinuing treatment remains the most secure course of action.

    Safer alternatives should be considered. The preferred medication for treating anxiety during pregnancy is sertraline SSRIs because these drugs pose the least risk for congenital disabilities. Research indicates that SSRIs may lead to minor neonatal adaptation syndrome; however, jitteriness and short-lived feeding issues typically resolve within the first few days after birth (Garakani et al., 2020). The pregnancy safety data for buspirone remains unclear, but the medication stands as an alternative treatment. The non-addictive characteristic of Hydroxyzine makes it suitable for short-term prescribing. Healthcare providers should consider non-drug strategies such as cognitive behavioral therapy (CBT) and mindfulness techniques.

    To avoid withdrawal symptoms, a structured tapering plan should be followed. Depending on tolerance, the dose should be reduced by 0.25 mg every 1-2 weeks. Common withdrawal symptoms include restlessness, anxiety, irritability, insomnia, dizziness, and nausea. More severe symptoms, such as hallucinations or seizures, require immediate medical attention (Meng et al., 2023). The patient should be encouraged to adopt relaxation techniques, maintain follow-up appointments, and utilize non-pharmacological coping strategies to facilitate a smoother transition.

    Anxiety left untreated pushes up maternal cortisol levels, which in turn raises the chances for early birth weight problems and slowed brain development (Brandt et al., 2024). Children of anxious mothers develop heightened attention struggles alongside emotional instability problems. Uncontrolled anxiety affects both parent and baby by leading to lower self-care habits and worsening dietary patterns while raising postpartum depression risk. NURS-6630 Week 5: Assignment De-Prescribing Telling the patient about safer ways to manage anxiety will benefit both her health and that of her unborn child.

    Medication Order

    Medication
    : Sertraline

    Dose
    : 25 mg

    Administration Route
    : Oral

    Dosage Schedule
    : Once per day

    Total Dispensed
    : 30 tablets

    Number of Refills
    : Two

    Special Instructions
    : Increase to 50 mg after two weeks if tolerated. Follow-up in four weeks.

    Medication
    : Lorazepam

    Dose
    : 0.5 mg

    Route
    : Oral

    Dosage Schedule
    : Two times per day

    Total Dispensed
    : 20 tablets

    Refills
    : None

    Special Instructions
    : Reduce by 0.25 mg every 1-2 weeks. Monitor for withdrawal symptoms. Follow up every two weeks.

    Patient 4: Reducing Fall Risk and Cognitive Decline in Elderly Patients Due to Benzodiazepines

    The patient is a 71-year-old man experiencing progressive memory decline and repeated falls that suggest possible early dementia. His current medications include clonazepam, which affects older adult cognition through sedative effects along with heightened fall susceptibility. Medical experts recommend discontinuing treatment because of the dangerous side effects.

    Benzodiazepines administered over prolonged periods confuse poor motor coordination and increase the risk of fractures as a result of falls (Fung et al., 2024). Studies have shown that these drugs create new dementia conditions while simultaneously making patients’ cognitive abilities worsen. Medical professionals need to advise both the patient and his daughter that stopping clonazepam could lead to improved cognitive function and reduced fall hazards.

    A thorough assessment should determine the full extent of clonazepam’s health effects. The Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE) both assess memory functions as part of their evaluation process. A medication review process identifies harmful drug interactions that impact balance functions and cognitive abilities (Rosenthal & Burchum, 2021). A professional evaluation of walking mechanics and postural stability should be conducted during assessment procedures. The daughter’s direct observations of both behavioral modifications and instances of falling will generate valuable analysis. Regular follow-up appointments allow practitioners to adjust the tapering plan as needed.

    Gradual tapering is necessary to reduce withdrawal risks. The recommended tapering schedule involves reducing clonazepam by 0.125 mg every two weeks, rather than 0.25 mg, to provide a slower withdrawal process (Rosenthal & Burchum, 2021). The patient and his daughter should be educated on withdrawal symptoms. Mild symptoms include irritability, restlessness, insomnia, dizziness, and headaches. Moderate symptoms, such as nausea, muscle tension, and worsening anxiety, may require taper adjustments. Severe symptoms, including confusion, hallucinations, seizures, or agitation, require immediate medical care. The patient’s daughter should monitor symptoms and ensure adherence to the tapering plan. Sleep hygiene, light physical activity, and relaxation techniques should be encouraged.

    Medical professionals should evaluate alternative treatments when patients develop worse anxiety following discontinuation. According to Montes-Castrejon et al. (2024). Sertraline, along with other SSRIs, delivers prolonged anxiety relief while keeping patients alert. Cognitive behavioral therapy (CBT), balance therapy, home safety modifications, and other non-drug interventions should be combined to support physical and cognitive health.

     

     

    Medication Order

    Medication
    : Clonazepam

    Dose
    : 0.5 mg

    Route
    : Oral

    Frequency
    : Twice daily

    Quantity
    : 20 tablets

    Refills
    : None

    Instructions
    : Decrease the dose by 0.125 mg every two weeks. Monitor closely for withdrawal symptoms. Schedule follow-ups to assess progress and adjust tapering as needed.

    Conclusion

    Elderly patients need careful de-prescribing of benzodiazepines because a gradual withdrawal plan reduces negative effects on cognitive and physical well-being. The patient safety process requires a gradual decrease in medications, which helps avoid serious withdrawal symptoms. The combination of SSRIs with therapy, together with effective fall prevention methods, presents patients with safer long-term treatment options. NURS-6630 Week 5: Assignment De-Prescribing Patient education and regular check-ups are indispensable in creating a successful benzodiazepine tapering process that focuses on patient wellness.

    References

    Archer, C., Wiles, N., Kessler, D., Chew-Graham, C. A., & Turner, K. (2024). Prescribing benzodiazepines in young adults with anxiety: A qualitative study of GP perspectives.
    British Journal of General Practice
    , BJGP.2024.0211–BJGP.2024.0211.
    https://doi.org/10.3399/bjgp.2024.0211

    Brandt, J., Bressi, J., Lê, M.-L., Neal, D., Cadogan, C., Witt-Doerring, J., Witt-Doerring, M., & Wright, S. (2024). Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: An international scoping review.
    EClinicalMedicine
    ,
    70
    , 102507–102507.
    https://doi.org/10.1016/j.eclinm.2024.102507

    Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021). Benzodiazepines: Uses, dangers, and clinical considerations.
    Neurology International
    ,
    13
    (4), 594–607.
    https://doi.org/10.3390/neurolint13040059

    Finlayson, A. J. R., Macoubrie, J., Huff, C., Foster, D. E., & Martin, P. R. (2022). Experiences with benzodiazepine use, tapering, and discontinuation: An internet survey.
    Therapeutic Advances in Psychopharmacology
    ,
    12
    , 204512532210823.
    https://doi.org/10.1177/20451253221082386

    Fung, C. H., Alessi, C., Martin, J. L., Josephson, K., Kierlin, L., Dzierzewski, J. M., Moore, A. A., Badr, M. S., Zeidler, M., Kelly, M., Smith, J. P., Cook, I. A., Der-Mcleod, E., Ghadimi, S., Naeem, S., Partch, L., Guzman, A., Grinberg, A., & Mitchell, M. (2024). Masked taper with behavioral intervention for discontinuing benzodiazepine receptor agonists: A randomized clinical trial.
    JAMA Internal Medicine
    ,
    184
    (12), 1448–1456.
    https://doi.org/10.1001/jamainternmed.2024.5020

    Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020). Pharmacotherapy of anxiety disorders: Current and emerging treatment options.
    Frontiers in Psychiatry
    ,
    11
    (595584). https://doi.org/10.3389/fpsyt.2020.595584

    Meng, L.-C., Lin, C.-W., Chuang, H.-M., Chen, L.-K., & Hsiao, F.-Y. (2023). Benzodiazepine use during pregnancy and risk of miscarriage.
    JAMA Psychiatry
    , e234912.
    https://doi.org/10.1001/jamapsychiatry.2023.4912

    Montes-Castrejon, A., Moncayo-Samperio, L. G., & Flores-Ramos, M. (2024). Benzodiazepine consumption, functionality, cognition, and somnolence in older adults at a tertiary care psychiatric hospital in Mexico City.
    Cureus
    . https://doi.org/10.7759/cureus.53252

    Rosenthal, L. D., & Burchum, J. R. (2021).
    Lehne’s pharmacotherapeutics for advanced practice nurses and physician assistants
    (2nd ed.). Elsevier NURS-6630 Week 5: Assignment De-Prescribing.

     

    NURS-6630 Week 5: Assignment De-Prescribing

    De-Prescribing

    What is the importance of de-prescribing? How might you assist a patient to taper from a medication safely or transition to a new medication?

    In this Assignment, you will use the following patient examples to write a 5- to 6-page paper on considerations you have for how you might de-prescribe. Support your answers with five (5) evidence-based, peer-reviewed scholarly literature resources outside of Required Learning Resources in this course.

    Note:
     APA style format guidelines will apply.

    Patient Examples:

    Patient 1:
     A 36-year-old male presents to your office being prescribed by his primary care physician (PCP) for the past 3 years an opioid analgesic medication for a work accident. He has chronic pain and is attending a pain clinic. It is determined the best course of treatment for pain is to remain on opioid medication. The patient is also being prescribed clonazepam 1mg BID for “relaxation” and panic attacks.

    Patient 2:
     A 42-year-old female on alprazolam 1mg BID for panic attacks. Panic attacks have been in remission and the patient wants to taper off the medication. But, every time she has attempted to do so in the past, she experienced withdrawal effects. She is wondering how to safely taper off the benzodiazepine medication without having withdrawal effects.

    Patient 3:
     A 24-year-old female prescribed lorazepam 1mg TID for generalized anxiety disorder. She recently found out she is pregnant (9 weeks gestation). She was referred to you by her OB-GYN to discuss this medication for her current situation. The patient is wondering if she can stay on the lorazepam through her pregnancy and postpartum, as it is an effective medication for anxiety symptoms. She plans to exclusively breastfeed for the first 6 months postpartum. She has not had any other trials of medication to treat anxiety as lorazepam has been effective.

    Patient 4:
     A 71-year-old-male who comes to see you at the insistence of his daughter. His daughter expresses concern of memory loss and is wondering if he has the beginning stages of dementia. He is forgetful and seems to be tripping on things or walking into walls, although he has lived in the same home for the past 35 years. The patient does not agree with his daughter but does admit he has had a “few stumbles and falls” lately. Medication reconciliation shows the following medications: metoprolol ER 50mg q day, omeprazole 20mg q day, clonazepam 1mg TID, levothyroxine 75mcg q am. His daughter is wondering if he should be started on a “dementia medication.”

    Resources

     

    Be sure to review the Learning Resources before completing this activity.

    Click the weekly resources link to access the resources.

    WEEKLY RESOURCES

    To prepare for this Assignment:

    Review the assigned Learning Resources for this week.

    Review the definitions presented in your text and resources for de-prescribing and tapering.

    Consider the importance of de-prescribing.

    NURS-6630 Week 5:
    Assignment
    De-Prescribing

    Based on the example(s) provided, consider how you might de-prescribe a patient.

    The Assignment

    Answer the following questions using the patient examples described above.

    Patient 1

    What are the concerns of the patient remaining on the opioid medication and clonazepam?

    How might you educate the patient about these risks and concerns?

    The patient agrees that he should not continue both medications in combination. He would like to “get off” the clonazepam but worries about “bad withdrawals” that he’s heard about from stopping clonazepam “cold turkey” and is concerned about re-occurring panic attacks. How might you respond to the following:

    How would you instruct the patient to taper off clonazepam?

    What other medication would you recommend for the patient for the treatment of his panic attacks? Keep in mind, he will continue the opioid medication for pain relief.

    How would you start the new recommended psychotropic medication for the patient?

    Discuss one legal, ethical, or social consideration with the treatment plan.

    Patient 2

    The patient reports withdrawal symptoms when previously tapering off the alprazolam. What symptoms are common withdrawal symptoms from this medication?

    Provide the patient education of withdrawal symptoms that range from common and less serious to withdrawal symptoms that are a cause for concern and that should prompt patient should seek medical attention.

    Given the patient’s history of having withdrawal effects from attempting to taper off alprazolam, what longer-acting benzodiazepine would you choose to convert the patient to?

    What is the dose you would prescribe and how would you taper off the medication?

    Patient 3

    Review the potential risks, benefits, and side effects of continuing lorazepam throughout the pregnancy and postpartum for both the patient and fetus.

    Review other alternative medications to treat generalized anxiety disorder. Include risks, benefits, and potential side effects to both the patient and the developing fetus. Keep in mind, the patient is looking to breast feed for 6 months postpartum.

    The patient agrees that it would be safest for her pregnancy and fetus to discontinue the lorazepam. How would you recommend she discontinue lorazepam? Provide education on potential side effects from tapering off the medication, including common side effects to more serious side effects and when to seek medical attention.

    The patient would like to forgo medications at this time, given she is early in her pregnancy and is concerned about “damage” to the fetus if she were to continue medications. Provide education to the patient about the risks of untreated anxiety symptoms during pregnancy for both the patient and the fetus NURS-6630 Week 5: Assignment De-Prescribing.

    Patient 4

    Review potential side effects for elderly on benzodiazepines providing education to both the patient and the patient’s daughter. What are the risks of continuing the benzodiazepine for this patient?

    How would you evaluate the patient for these side effects?

    The patient and daughter agree he will need to taper off the clonazepam given the risks of continuing this medication. How would you recommend tapering off this medication?

    Review with the patient and daughter potential side effects of tapering off the medication. Review with them common side effects to more serious side effects and when to seek medical attention.

    Reminder:
     The College of Nursing requires that all papers submitted include a title page, introduction, summary, and references. The 
    Walden Writing Center Sample Paper
    Links to an external site.
     provides an example of those required elements.

    By Day 7

    Submit
     your Assignment by 
    Day 7 of Week 5
    .

    submission information

    Before submitting your final assignment, you can check your draft for authenticity. To check your draft, access the 
    Turnitin Drafts
     from the 
    Start Here
     area.

    To submit your completed assignment, save your Assignment as 
    WK5Assgn_LastName_Firstinitial

    Then, click on 
    Start Assignment
     near the top of the page.

    Next, click on 
    Upload File
     and select 
    Submit Assignment
     for review.

    Rubric

    NURS_6630_Week5_Assignment_Rubric

    NURS_6630_Week5_Assignment_Rubric

    Criteria

    Ratings

    Pts

    This criterion is linked to a Learning Outcome
    Patient 1: Describes concerns for patient remaining on the medication and how these risks and concerns will be addressed to the patients. Describes how to assist Patient 1 in tapering medication, as well as what other medication might be prescribed with considerations of legal, ethical, or social considerations to the plan.

    20
     
    to >
    18.0
     pts
    Excellent
    The response comprehensively describes medication risks and concerns. The response comprehensively and clearly explains how the patient will be educated. The response comprehensively and clearly explains considerations for medication tapering. The response comprehensively and clearly reflects on legal, ethical, or social considerations of the plan NURS-6630 Week 5: Assignment De-Prescribing.

    18
     
    to >
    15.0
     pts
    Good
    The response clearly describes medication risks and concerns. The response clearly explains how the patient will be educated. The response clearly explains considerations for medication tapering. The response clearly reflects on the legal, ethical, or social considerations of the plan.

    15
     
    to >
    10.0
     pts
    Fair
    The response inaccurately or vaguely describes medication risks and concerns. The response inaccurately or vaguely explains how the patient will be educated. The response inaccurately or vaguely explains considerations for medication tapering. The response inaccurately or vaguely reflects on legal, ethical, or social considerations of the plan.

    10
     
    to >
    0
     pts
    Poor
    The response vaguely or inaccurately describes medication risks and concerns, or it is missing. The response includes inaccurate and vague examples that does not explain how the patient will be educated, or it is missing. The response vaguely or inaccurately explains considerations for medication tapering, or it is missing. The response includes inaccurate and vague examples that does not reflect on legal, ethical, or social considerations of the plan, or it is missing.

    20
     pts

    This criterion is linked to a Learning Outcome
    Patient 2: Describes common withdrawal symptoms and patient education information. Describes which benzodiazepine might be prescribed to convert the patient, as well as the specific dosing and tapering information.

    20
     
    to >
    18.0
     pts
    Excellent
    The response comprehensively and clearly explains withdrawal symptoms. The response comprehensively and clearly provides patient education information. The response comprehensively and clearly identifies a benzodiazepine for the patient. The response comprehensively and clearly details dosing and tapering information.

    18
     
    to >
    15.0
     pts
    Good
    The response clearly explains withdrawal symptoms. The response clearly provides patient education information. The response clearly identifies a benzodiazepine for the patient. The response clearly details dosing and tapering information.

    15
     
    to >
    10.0
     pts
    Fair
    The response inaccurately or vaguely explains withdrawal symptoms. The response inaccurately or vaguely provides patient education information. The response inaccurately or vaguely identifies a benzodiazepine for the patient. The response inaccurately or vaguely details dosing and tapering information.

    10
     
    to >
    0
     pts
    Poor
    The response vaguely or inaccurately explains withdrawal symptoms, or it is missing. The response includes inaccurate and vague examples that does not provide patient education information, or it is missing. The response vaguely or inaccurately identifies a benzodiazepine for the patient, or it is missing. The response includes inaccurate and vague examples that does not detail dosing and tapering information, or it is missing.

    20
     pts

    This criterion is linked to a Learning Outcome
    Patient 3: Describes potential risks, benefits and side effects of lorazepam, as well as alternative medications that might be prescribed for the patient. Describes how the patient might discontinue lorazepam, with necessary patient education regarding discontinuing medication and patient/fetus needs.

    20
     
    to >
    18.0
     pts
    Excellent
    The response comprehensively and clearly describes risks, benefits and side effects of lorazepam. The response comprehensively and clearly identifies potential alternative medications. The response comprehensively and clearly describes how the patient might discontinue the medication. The response comprehensively and clearly provides necessary education for discontinuing the medication for patient and fetus.

    18
     
    to >
    15.0
     pts
    Good
    The response clearly describes risks, benefits and side effects of lorazepam. The response clearly identifies potential alternative medications. The response clearly describes how the patient might discontinue the medication. The response clearly provides necessary education for discontinuing the medication for patient and fetus.

    15
     
    to >
    10.0
     pts
    Fair
    The response inaccurately or vaguely describes risks, benefits and side effects of lorazepam. The response inaccurately or vaguely identifies potential alternative medications. The response inaccurately or vaguely describes how the patient might discontinue the medication. The response inaccurately or vaguely provides necessary education for discontinuing the medication for patient and fetus.

    10
     
    to >
    0
     pts
    Poor
    The response vaguely or inaccurately describes risks, benefits and side effects of lorazepam, or it is missing. The response includes inaccurate and vague examples that does not identify potential alternative medications, or some or all are missing. The response vaguely or inaccurately describes how the patient might discontinue the medication, or it is missing. The response includes inaccurate and vague examples that does not provide necessary education for discontinuing the medication for patient and fetus, or some or all are missing.

    20
     pts

    This criterion is linked to a Learning Outcome
    Patient 4: Describes potential risks and side effects of continuing benzodiazepine. Describes how to taper the medication and education regarding the tapering. NURS-6630 Week 5: Assignment De-Prescribing

    20
     
    to >
    18.0
     pts
    Excellent
    The response comprehensively and clearly describes potential side effects and risks. The response comprehensively and clearly describes how to taper the medication. The response comprehensively and clearly provides necessary patient education for tapering.

    18
     
    to >
    15.0
     pts
    Good
    The response clearly describes potential side effects and risks. The response clearly describes how to taper the medication. The response clearly provides necessary patient education for tapering.

    15
     
    to >
    10.0
     pts
    Fair
    The response inaccurately or vaguely describes potential side effects and risks. The response inaccurately or vaguely describes how to taper the medication. The response inaccurately or vaguely provides necessary patient education for tapering.

    10
     
    to >
    0
     pts
    Poor
    The response vaguely or inaccurately describes potential side effects and risks, or it is missing. The response vaguely or inaccurately describes how to taper the medication, or it is missing. The response includes inaccurate and vague examples that does not provide necessary patient education for tapering, or some or all are missing.

    20
     pts

    This criterion is linked to a Learning Outcome
    Paper demonstrates critical thinking and synthesis of literature with five (5) evidence-based, peer reviewed scholarly references

    5
     
    to >
    4.0
     pts
    Excellent
    Paper demonstrates critical thinking and synthesis of literature with five (5) evidence-based, peer reviewed scholarly references outside of course resources.

    4
     
    to >
    3.0
     pts
    Good
    Paper demonstrates some critical thinking and/or vague synthesis of literature with four (4) evidence-based, peer reviewed scholarly references outside of course resources.

    3
     
    to >
    1.0
     pts
    Fair
    Paper demonstrates vague critical thinking and/or little synthesis of literature with three (3) evidence-based, peer reviewed scholarly references.

    1
     
    to >
    0
     pts
    Poor
    Paper demonstrates no critical thinking and/or synthesis of literature with two (2) or less evidence-based, peer reviewed scholarly references.

    5
     pts

    This criterion is linked to a Learning Outcome
    Written Expression and Formatting—Paragraph Development and Organization: Paragraphs make clear points that support well-developed ideas, flow logically, and demonstrate continuity of ideas. Sentences are carefully focused—neither long and rambling nor short and lacking substance. A clear and comprehensive purpose statement and introduction is provided, which delineates all required criteria.

    5
     
    to >
    4.0
     pts
    Excellent
    Paragraphs and sentences follow writing standards for flow, continuity, and clarity. A clear and comprehensive purpose statement, introduction, and conclusion is provided which delineates all required criteria.

    4
     
    to >
    3.0
     pts
    Good
    Paragraphs and sentences follow writing standards for flow, continuity, and clarity 80% of the time. Purpose, introduction, and conclusion of the Assignment is stated yet is brief and not descriptive.

    3
     
    to >
    1.0
     pts
    Fair
    Paragraphs and sentences follow writing standards for flow, continuity, and clarity 60%–79% of the time. Purpose, introduction, and conclusion of the Assignment is vague or off topic.

    1
     
    to >
    0
     pts
    Poor
    Paragraphs and sentences follow writing standards for flow, continuity, and clarity less than 60% of the time. No purpose statement, introduction, or conclusion was provided.

    5
     pts

    This criterion is linked to a Learning Outcome
    Written Expression and Formatting—English writing standards: Correct grammar, mechanics, and proper punctuation

    5
     
    to >
    4.0
     pts
    Excellent
    Uses correct grammar, spelling, and punctuation with no errors.

    4
     
    to >
    3.0
     pts
    Good
    Contains one or two grammar, spelling, and punctuation errors.

    3
     
    to >
    1.0
     pts
    Fair
    Contains several (three or four) grammar, spelling, and punctuation errors.

    1
     
    to >
    0
     pts
    Poor
    Contains many (five or more) grammar, spelling, and punctuation errors that interfere with the reader’s understanding.

    5
     pts

    This criterion is linked to a Learning Outcome
    Written Expression and Formatting: The paper follows correct APA format for title page, headings, font, spacing, margins, indentations, page numbers, parenthetical/in-text citations, and reference list.

    5
     
    to >
    4.0
     pts
    Excellent
    Uses correct APA format with no errors.

    4
     
    to >
    3.0
     pts
    Good
    Contains one or two APA format errors.

    3
     
    to >
    1.0
     pts
    Fair
    Contains three or four APA format errors.

    1
     
    to >
    0
     pts
    Poor
    Contains many (five or more) APA format errors.

    NURS-6630 Week 5: Assignment De-Prescribing

    5
     pts

    Total Points: 
    100

  • Alopecia areata

    Question 26                    1 pts

    A patient is seen in the clinic for patches of hair loss. The provider notes several well-demarcated patches on the scalp and eyebrows without areas of inflammation and several hairs within the patch with thinner shafts near the scalp. Based on these findings, which type of alopecia is most likely?

    Group of answer choices

     

    Alopecia areata

     

    Anagen effluvium

     

    Cicatricial alopecia

     

    Telogen effluvium